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Abstract 
Peptide-based epitope tagging technology is universally used in nearly all kind 
of research projects that involve biochemical characterization of a target protein, but not 
many systems are fully compatible with purification purpose. By utilizing an 
anti-human podoplanin antibody NZ-1, I constructed a novel epitope tagging system. 
NZ-1 possesses exceptionally high affinity toward a dodecapeptide 
(GVAMPGAEDDVV) dubbed PA tag, with a characteristic slow dissociation kinetics. 
Because of its high affinity, PA-tagged proteins in a dilute sample can be captured by 
immobilized NZ-1 resin in a near complete fashion and eluted by a solution of free PA 
peptide. This enabled efficient one-step purification of various proteins including 
soluble (e.g., an ectodomain fragment of neuropilin-1 and a human serum albumin) and 
membrane proteins expressed in mammalian cells. Mild regeneration condition of the 
peptide-bound antibody ensures repeated use of the antibody resin, indicating a 
cost-efficient nature of the system. PA tag/NZ-1 system also exhibits an outstanding 
performance in the immunodetection experiments (i.e., Western blotting and flow 
cytometry). An alanine scanning mutagenesis experiment revealed that many amino 
acid residues within the PA tag sequence contribute to the binding by NZ-1. To 
understand the molecular details of the PA tag-NZ-1 interaction at atomic resolution, I 
determined the X-ray crystal structure of the NZ-1 Fab fragment in complex with the PA 
tag peptide. In the structure, the PA peptide is docked in the antigen-binding cleft of the 
NZ-1, and there are numerous contacts involving the peptide region encompassing 
Met4-Asp10. In the NZ-1-bound conformation, the PA peptide assumed a tight 
2-residue type II -turn conformation at the Pro5-Gly6 sequence. This binding mode 
suggested an interesting possibility that PA tag may be inserted into a loop region of 
proteins, without losing its high affinity toward NZ-1. Using a cell adhesion receptor 
integrin IIb3 as a model protein, I successfully inserted the PA tag into multiple loop 
regions in the ectodomain of IIb3 and confirmed that all proteins were reactive with 
NZ-1. Moreover, by choosing the site of PA tag insertion, it was possible to modulate 
the function of resultant integrin by inducing conformational change upon the addition 
of NZ-1. As it is generally difficult to graft linear epitope tag in a structured protein 
domain, the PA tag system provide unique opportunity to attach purification/labeling 
handle to a target protein. 
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1Chapter I 
An affinity tag system is a necessary technique for a modern bioscience 
research and development, because it is almost impossible to detect, visualize, and 
purify a target protein without this technique. Especially, purification technique using 
affinity tag is important for the success of the structure-function research on the front 
line. In the basic biomedical research, there are many cases where we do not understand 
the exact molecular function of the proteins of interest even if the physiological 
importance is established. To analyze the functions of such proteins at molecular level, 
it is often necessary to perform experiments using purified proteins. Generally, a target 
protein is expressed in Escherichia coli, mammalian cells, or insect cells using 
gene-recombination technique for analysis of protein function. It is difficult to analyze 
the function of target proteins directly in these cells, because the environment in the 
host cells is very different from the original location of the target proteins. Therefore, it 
is often necessary to reconstruct the proper environment with purified protein. Moreover, 
to determine the three-dimensional structure of functional protein using X-ray 
crystallography, protein samples with high purify and quality are required. Although 
many protein samples are commercially available from companies these days, a target 
protein still must be prepared by oneself for an original research as before. Therefore, 
development of better affinity tag system is always wanted. 
 The affinity tag systems are used for the purification and detection of a target 
protein. A target protein attached with the specific amino acid sequence is captured by 
molecule that recognizes the sequence specifically. This amino acid sequence is called 
tag, and tag is usually fused to N- or C-terminal with a linker sequence to minimize 
unwanted effects on the conformation and activity of the target protein. An affinity tag 
purification system has several advantageous characteristics over conventional 
purification methods. For example, target proteins can be purified quickly and 
specifically by taking advantage of the specific molecular interaction of the tag system. 
The method is generally applicable to many target proteins because the principle of the 
separation does not depend on the nature of the target protein itself. In contrast, 
traditional chromatography methods for protein purification (ion-exchange 
chromatography, hydrophobic interaction chromatography, gel filtration 
chromatography, and so on) depend on physical-chemical property of each protein. 
Therefore, affinity tag purification method enables the purification of a target proteins 
2easily and quickly with fewer steps, without the detailed optimization for each protein. 
Biologically active proteins are generally unstable in solution, especially when they are 
isolated from their original environment (e.g., cell cytoplasm). Therefore, it is generally 
ideal to prepare the sample from the biological specimen within the minimum amount 
of time. It is unquestionable that shorter time requirement is also highly desirable for 
other experiments such as Western blotting and immunocytochemistry, to rapidly, 
examine protein expression and localization. 
So far, various affinity tag systems have been developed and become 
commercially available. The representative affinity tag systems include His tag 
(Hochuli et al. 1988), GST tag (Benard and Bokoch 2002), FLAG tag (Hopp et al. 
1988), HA tag (Field et al. 1988), Myc tag (Evan et al. 1985), Target tag (Tabata et al. 
2010). His tag consists of 6-10 histidine residues, and this tag system uses the property 
that consecutive histidine residues specifically bind to metal ion (e.g., Ni and Co) 
displayed with chelate agent. GST tag is composed of an enzyme 
glutathione-S-transferase (approximately 28 kDa), utilizing the enzyme-substrate 
specific binding to glutathione. The FLAG, HA, Myc, and Target tag consist of 
oligopeptides with unique amino acids sequence (FLAG tag: DYKDDDDK, HA tag: 
YPYDVPDYA, Myc tag: EQKLISEEDL, Target tag: 
YPGQYPGQYPGQYPGQYGQV). These tags can be recognized by proprietary 
monoclonal antibodies that are highly specific against each peptide sequence. Such tag 
systems are collectively called epitope tag system. 
In order to be an excellent affinity tag purification system, it must fulfill many 
features. For example, very high specificity and affinity between the tag and the binder 
molecule is indispensable. Also important is the ability to remove the bound target 
protein from the binder molecule without damaging the target, and to regenerate the 
immobilized resin for the next round of use. Unfortunately, a perfect system rarely 
exists. Therefore, we have to choose different tag systems for each case after careful 
comparison and optimization based on the nature of the target protein. For example, 
although the purification of His-tagged proteins using metal chelate affinity resin is an 
excellent choice because of the high capacity and low cost, it usually results in 
co-purification of metal-binding proteins present in the starting material, necessitating 
further purification steps (Lichty et al. 2005). GST tag system is superior to many other 
systems for expression in soluble fraction of E. coli, but its large size (~28 kDa) may 
3affect function of tagged proteins and it is usually required to removed the GST moiety 
by a protease treatment. 
The epitope tag systems such as FLAG, HA, and Myc have several 
advantages over other tagging technologies. These tags generally do not affect the 
function and structure of target proteins because they are small, and have high 
specificity owing to the antigen-antibody interaction. An epitope tag system such as 
very popular FLAG tag system (Einhauer and Jungbauer 2001) is suitable for the 
purification of a low-abundance, precious target protein. However, the antibody 
immobilized resin for purification has relatively low binding capacity, and it is of high 
cost. Moreover, even the most successful system like FLAG tag/anti-FLAG M2 
antibody sometimes suffers from non-specific binding of endogenous proteins in certain 
cell types (Kato et al. 2003; Sasaki et al. 2012). Another disadvantages of FLAG tag 
system include the problem of the limited reusability. Although the column regeneration 
condition recommended by the vendor (treatment with an acidic buffer at pH 3.0) works 
fine, many users confirmed that this condition gradually deactivate the M2 immobilized 
resin. Therefore, there is a continuous need for the development of new affinity tag 
system with high affinity, high specificity, and high reusability. In this research, I aimed 
at a development of a novel affinity tag system superior to the existing tag systems. 
Generally, affinity tag is fused to either the N- or C- terminal of a target 
protein to facilitate affinity purification and detection, because the tag insertion into the 
middle of a sequence of a target protein may destroy the local conformation or alter its 
function. Even when the tag sequence insertion is not expected to affect the function of 
target protein, such attempts are rare, because the inserted tag does not usually work as 
a tag any more due to the limited antibody accessibility and/or the altered conformation. 
However, we sometimes come across cases where protein terminals are important for 
the function, or buried and not accessible to a binder. In such cases, we have to seek 
ways to attach tags somewhere else. Therefore, there are unmet needs for the 
development of general tagging system that is compatible with the tag insertion. 
There are several studies reporting successful insertion of tag sequence in the middle of 
a protein by targeting at flexible loop region that does not have secondary structure. In 
these reports, however, either very long loops were chosen as the insertion point 
(Dinculescu et al. 2002; Smith et al. 2004; Morlacchi et al. 2012) or the inserted tag was 
flanked by long linker sequences (Facey and Kuhn 2003; Kendall and Senogles 2006). 
4Even the inserted tag sequence itself is sometimes very long, because of the inclusion of 
multiple tag sequences in tandem (Kobayashi et al. 2008; Zakrzewska et al. 2009). 
Although these strategies are necessary to make the tag recognizable by the antibody, 
they change the local structure of the protein significantly and are rarely compatible 
with the folded protein domain. As a result, we still lack general and versatile 
tag-insertion technology and one need to apply sophisticated knowledge of protein 
engineering to achieve successful epitope grafting (Laird and Desrosiers 2007). Thus it 
is of great importance to develop simple and general way to insert an epitope tag into 
the middle of a sequence of a target protein. If successful, such tag may also be used in 
different application including the site-specific labeling of a receptor. Therefore, I 
decided to investigate whether a novel affinity tag (PA tag) can be inserted into a tip of 
turn or in the middle of a loop region of a target protein. 
In this thesis, I describe the construction of PA tag system in Chapter II. In 
Chapter III, I describe the structural characterization of the PA tag system and its 
application in the development of a unique epitope grafting method. 
5Chapter II 
Introduction 
 An excellent epitope tag system needs the combination of a peptide tag and a 
monoclonal antibody with high specificity and affinity. However, it is very difficult that 
we obtain the combination as described above. In fact, the popular epitope tag systems 
use antibodies that were established to recognize the target protein. HA tag monoclonal 
antibody was established to recognize human influenza hemagglutinin (Field et al. 
1988), and Myc tag monoclonal antibody was established to recognize c-Myc (Evan et 
al. 1985). Meanwhile, FLAG tag monoclonal antibody is an exception. This antibody 
was established against the peptide including enterokinase sequence (DDDDK) to use 
for the epitope tag system (Hopp et al. 1988). Only FLAG tag system was currently 
developed by design. 
 Prof. Yukinari Kato et al., (Tohoku University) have established a unique rat 
monoclonal antibody NZ-1 directed against 14-residue peptide segment 
(EGGVAMPGAEDDVV) in human podoplanin PLAG domain (Kato et al. 2006). 
Podoplanin is a type I transmembrane protein highly expressed on malignant cancer 
cells and is implicated in tumor-induced platelet aggregation by binding to CLEC-2 on 
platelet surface (Kato et al. 2008). NZ-1 inhibits binding of podoplanin to CLEC-2 and 
is a potential lead for the antibody-based therapy against glioblastoma (Kaneko et al. 
2012; Kato et al. 2008). NZ-1 was raised against 14-residue peptide corresponding to 
residues 38-51 of human podoplanin (Ogasawara et al. 2008). Therefore, I attempted to 
prove that NZ-1 possesses desirable character as an anti-tag antibody.  
Here, I examined that this peptide tag and NZ-1 monoclonal antibody have 
high affinity and specificity, the peptide-tagged target protein is easy to be eluted by 
mild condition, and NZ-1 immobilized resin is able to be reused. As a result, the 
combination of the peptide tag derived from podoplanin and NZ-1 satisfied all the 
conditions. Moreover, it also exhibited an outstanding performance in the 
immunodetection experiments (i.e., Western blotting and flow cytometry). Therefore, I 
report a development of a novel affinity tag system consisting of NZ-1 and its epitope 
peptide (GVAMPGAEDDVV) dubbed PA tag. PA tag system proves to outperform 
many existing affinity tag systems owing to its high affinity, high selectivity, and 
extended reusability. 
6Materials and methods 
Construction of expression vectors 
 Expression constructs for the T4 lysozyme (T4L) attached with various tags 
shown in the Fig. I-1 (T4L-PA10, T4L-PA12, T4L-PA14, T4L-FLAG, T4L-HA, 
T4L-Myc, PA10-T4L, PA12-T4L, PA14-T4L, FLAG-T4L, HA-T4L, Myc-T4L) were 
prepared by extension PCR and cloned into NcoI-BamHI site of pET16b vector 
(Novagen). All constructs contained either C-terminal His × 8 or N-terminal His × 10 
tags to facilitate protein purification. These constructs attached with FLAG, HA, or Myc 
tag were prepared as template that was mutated from 1st Met derived from T4L to Lys 
using QuikChange strategy (Agilent). Single-residue alanine substitution mutants (G1A, 
V2A, M4A, P5A, G6A, E8A, D9A, D10A, V11A, V12A) of T4L-PA12 were also 
produced using QuikChange strategy. The primer list for this research was shown in 
Table I-1. Construct for GFPUV-PA12 was prepared by replacing T4L segment of 
T4L-PA12 with the coding sequence of GFPUV (Clontech). 
Full-length DNA for human isocitrate dehydrogenase 1 was attached with 
tandem FLAG and PA12 tags at the C-terminal (IDH1-FLAG-PA12) and cloned into 
pcDNA3.1 vector (Life Technologies Corp.) as described previously (Kaneko et al. 
2013b). For the construction of mNrp1ec-PA12, DNA encoding the entire ectodomain of 
mouse neuropilin-1 (a gift from Prof. A. Kumanogoh, Osaka University) and the linker 
+ PA12 segment from T4L-PA12 were fused by extension PCR and cloned into 
HindIII-XbaI site of pcDNA3.1 vector. For the construction of full-length rat 
neuropilin-2 tagged with PA12 tag, rNrp2-mCherry in pSecTag2A vector (a gift from 
Prof. Y. Goshima, Yokohama City University) was used to insert PA12 + linker segment 
(taken from the PA12-T4L) after the signal sequence, and cloned into XhoI-XhoI site of 
pcDNA3.1 vector (PA12-rNrp2-mCherry). The cDNA for human serum albumin (HSA) 
was obtained from Danaform (ID; 100009048). Construct for PA12-HSA was prepared 
by replacing rNrp2-mCherry of PA12-rNrp2-mCherry with the coding sequence of HSA 
using BamHI-BamHI site. Construct for HSA-PA12 was used to insert PA12 + linker 
segment (taken from the T4L-PA12), and cloned into EcoRI-XbaI site of pcDNA3.1 
vector. All constructs were verified by DNA sequencing. 
7Figure I-1. Expression constructs of recombinant proteins used in Chapter I. Amino acid 
sequences of the artificially added tag and the linker segments are shown. SS, signal sequence. 
8Table I-1. Primer list
9Table I-1. Primer list (continued)
Antibodies used 
The rat anti-PA monoclonal antibody NZ-1 (IgG2a, ) was provided by Prof. Y. 
Kato (Kato et al. 2006). The mouse anti-FLAG monoclonal antibody M2, the 
HRP-conjugated rabbit anti-rat IgG polyclonal antibody, and the HRP-conjugated goat 
anti-mouse IgG polyclonal antibody were obtained from Sigma-Aldrich. The mouse 
anti-HA monoclonal antibody 4B2 and the mouse anti-Myc monoclonal antibody 9E10 
were obtained from Wako Pure Chemical Industries Ltd. The FITC-conjugated goat 
anti-rat IgG polyclonal antibody was obtained from Beckman Coulter Inc. 
Expression and purification of T4L 
 The tagged T4L proteins were expressed in transformed E. coli BL21 (DE3) 
cultured at 37 °C in liquid LB medium containing 50 g/ml ampicillin until OD600
(Optical Density at 600 nm) was reached to ~0.6. The T4L expression was induced by 
the culture for ~3 h at 37 °C in the presence of 1 mM IPTG. The T4L proteins were 
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purified as described below. Culture medium was centrifuged. The cells were suspended 
in TBS (pH 7.5) [20 mM Tris-HCl, 150 mM NaCl], and were sonicated. Then the 
suspension was centrifuged, and the soluble fraction (supernatant) was collected. The 
soluble fraction was mixed with Ni-NTA Agarose (QIAGEN) and incubated for 0.5~1 h 
at 4 °C under gentle agitation. The beads were transferred to a small column, washed 
with wash buffer [20 mM Tris-HCl (pH 8.0), 300 mM NaCl, 20 mM imidazole], and the 
bound protein was eluted with elution buffer [20 mM Tris-HCl (pH 7.0), 300 mM NaCl, 
250 mM imidazole]. The elution samples were dialyzed against PBS (pH 6.0) [100 mM 
phosphate 100 mM NaCl]. 
 Besides, the constructs for T4L attached with tag at the N-terminal (e.g., 
PA10-T4L, PA12-T4L, PA14-T4L) were used for the mutated constructs that were 
mutated from 1st Met derived from T4L to Lys for stopping the translation on the way, 
because these non-mutated constructs expressed the proteins that the translation started 
at the downstream Met derived form T4L. 
Binding kinetics analysis using bio-layer interferometry (BLI) 
 Binding kinetics of various antibodies toward T4L protein tagged with their 
respective antigen peptide was analyzed by BLI using Octet RED system (Pall 
ForteBio). Binding assays were performed in 96-well microtiter plates at 30 °C with 
orbital sensor agitation at 1,000 rpm. Amine Reactive (AR2G) sensors were 
immobilized with each antibody dissolved at 10-20 g/ml in 10 mM sodium acetate 
buffer at pH 6.0, followed by quenching with 1 M ethanolamine at pH 8.5. Binding to 
the serially diluted tagged proteins (1 nM, 3 nM, 10 nM, 30 nM) in PBS containing 
0.005% Tween 20 (PBST) with 1% BSA placed in different wells at a volume of 200 l 
was monitored for 60 s, followed by dissociation in PBST for 120 s. Binding curves 
were analyzed by BIAevaluation software (GE Healthcare) with a curve-fitting using a 
1:1 binding model. 
Binding kinetics analysis using surface plasmon resonance (SPR) 
All SPR experiments were performed using BIACORE 2000 instrument (GE 
Healthcare). CM5 sensor chip were immobilized with NZ-1 dissolved in 10 mM sodium 
acetate buffer at pH 6.0 till approximately 3,000 RU (Resonance Unit) (1 RU » 1 
pg/mm2), followed by quenching with 1 M ethanolamine at pH 8.5. The PA-tagged T4L 
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proteins were diluted in PBST (3.125 nM, 6.25 nM, 12.5 nM, 25 nM) and injected at a 
flow rate of 20 l/min. Binding was monitored for 60 s, followed by dissociation in 
PBST for 120 s. This sensor chip was regenerated by incubation with 10 mM 
Glycin-HCl (pH 3.0), 1 M NaCl for 30 s. Binding curves were analyzed by 
BIAevaluation software (GE Healthcare) with a curve-fitting using a 1:1 binding model. 
All single-residue alanine substitution mutants of T4L-PA12 were similarly 
measured. However, all mutated T4L-PA12 were injected at the concentration of 20 nM. 
Western blot analysis of IDH1-FLAG-PA12 
 Human osteosarcoma U-2 OS cells (obtained from the American Type Culture 
Collection (ATCC), Manassas, VA) were transiently transfected with 
IDH1-FLAG-PA12 and the cell lysate was prepared as described previously (Kaneko et 
al. 2013b) (a gift form Prof. Y. Kato). The lysate (10 g per lane) was separated on 10% 
SDS-PAGE and transferred to a PVDF membrane, followed by blocking with 4% skim 
milk in PBS (pH 7.4) with 0.05% Tween 20 for 15 min. For the primary antibody step, 
the membranes were incubated with varying concentrations of NZ-1 (0.01, 0.1, 1, or 3.5 
g/ml) or 3.5 g/ml anti-FLAG M2 diluted in TBS at pH 8.0, containing 0.05% Tween 
20 (TBST), for 1-60 min. For the secondary antibody step, membranes were incubated 
for 30 min with either HRP-conjugated rabbit anti-rat polyclonal antibody or 
HRP-conjugated goat anti-mouse polyclonal antibody (both from Sigma-Aldrich) 
diluted at 1:6,000 in TBST. Four consecutive washes (TBST, 5 min) were conducted 
between each step. The membranes were developed with ECL Prime reagent (GE 
Healthcare) and analyzed using ImageQuant LAS 4000mini (GE Healthcare). 
Flow cytometry analysis of the PA12-rNrp2-mCherry expression cells 
CHO-K1 cells (obtained from ATCC) were transiently transfected with 
PA12-rNrp2-mCherry construct. CHO-K1 cells were incubated by DMEM medium 
with 10% FCS, 1% Non-Essential Amino Acids solution (NEAA) (Sigma-Aldrich), and 
0.5% penicillin-streptomycin (Sigma-Aldrich) (DMEM/10% FCS). The medium of 
CHO-K1 cells incubated on the 6-well plate were changed to DMEM medium with 5% 
FCS, 1% NEAA, and 0.5% penicillin-streptomycin (DMEM/5% FCS), and the cells 
were transfected with PA12-rNrp2-mCherry plasmid DNA (2 g) using X-tremeGENE 
HP DNA Transfection Reagent (Roche). After 48 h incubation at 37 °C in 5% CO2, the 
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expression of PA12-rNrp2-mCherry was estimated by fluorescence microscope 
BZ-9000 (KEYENCE) using 540 nm/605 nm filter, and the cells were detached, washed 
twice, and resuspended in DMEM/5% FCS. The cells were then incubated with 
DMEM/5% FCS containing NZ-1 at various concentrations (0.01, 0.1, 1, or 10 g/ml) 
on ice for 30 min, washed twice with DMEM/5% FCS, and resuspended in DMEM/5% 
FCS containing FITC-conjugated goat anti-rat IgG antisera (Beckman Coulter Inc.) 
diluted at 1:100. After 30 min incubation on ice, the cells were washed once and 
suspended in PBS (pH 7.4), and analyzed on a flow cytometer with 488 nm laser 
(Guava EasyCyte, Millipore). 
Coupling of NZ-1 to resin (NZ-1-Sepharose) 
Purified NZ-1 was dialyzed against 0.1 M NaHCO3 (pH 8.3), 0.5 M NaCl. 
The purpose is final immobilization concentration ~2.0 mg IgG/ml, and CNBr-activated 
Sepharose 4FF (GE Healthcare) was measured equivalent for it, followed by Sepharose 
was swollen by adding 1 mM HCl. After swelling, Sepharose was washed three times 
by 1 mM HCl to remove the impurities. Sepharose was changed buffer to 0.1 M 
NaHCO3 (pH 8.3), 0.5 M NaCl, and added an antibody solution of the same volume as 
Sepharose, followed by incubated for ~3 h at room temperature under gentle agitation. 
After it was confirmed that there was few antibodies in supernatant using absorption 
spectrometer, the supernatant was removed, followed by Sepharose was incubated with 
0.1 M Tris-HCl (pH 8.0) for ~1.5 h at room temperature under gentle agitation for 
blocking. Next, the supernatant was removed, followed by Sepharose was washed once 
with 0.1 M NaHCO3 (pH 8.3), 0.5 M NaCl, once with MilliQ, once with 0.1 M NaAcO 
(pH 5.2), 0.5 M NaCl, and twice with TBS (pH 7.5). Finally, Sepharose was preserved 
50% slurry with TBS (pH 7.5). 
Expression and purification of mNrp1ec-PA12 
For the purification of soluble mNrp1ec-PA12 secreted from mammalian cells, 
HEK293T (obtained from ATCC) cells plated in a 15-cm culture dish were transiently 
transfected with the plasmid using Polyethylenimine (Sigma-Aldrich) and ~25 ml of 
culture supernatant was harvested ~72 h after the transfection. Cleared supernatant was 
mixed with NZ-1-Sepharose (250 l bed volume) and incubated for ~2 h at 4 °C under 
gentle agitation. The beads were then transferred to a small column (Bio-Rad), washed 
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with 5 ml (4 column × 5) of TBS (pH 7.5), and the bound protein was eluted with TBS 
containing 0.1 mg/ml free epitope peptide (EGGVAMPGAEDDVV). The elution was 
conducted at room temperature in a step-wise manner (1 column × 10), where 
dissociation time of 5 min was given for each elution step (Fig. I-2). The confirmation 
of purification quality was performed by all fractions were subjected to 10% 
SDS-PAGE and stained with CBB (Coomassie Brilliant Blue). 
Figure I-2. Outline of protein purification protocol using PA tag system.
The examination of purification condition was carried out using the same 
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mNrp1ec-PA12 culture supernatant. The culture supernatant was mixed with 
NZ-1-Sepharose at various volumes (1/50, 1/100, 1/200, or 1/400), was incubated for 
15-120 min (15 min, 30 min, 60 min, or 120 min), and was eluted by PA peptide at 
various concentrations (0.05 mg/ml, 0.075 mg/ml, 0.1 mg/ml, or 0.2 mg/ml). In the case 
of elution by high concentration MgCl2, this experiments was used 10 mM MES (pH 
6.0), 3 M MgCl2 or 10 mM MES (pH 6.0), 2 M MgCl2. The evaluations of purified 
protein quantity were measured by BCATM Protein Assay (Pierce), after all elution 
fractions were collected and dialyzed against TBS (pH 7.5). 
Western blot analysis of mNrp1ec-PA12 
 The culture supernatant and flowthrough that were obtained in the purification 
of mNrp1ec-PA12 were diluted at 1/2, 1/4, and 1/8 by TBS (pH 7.5). Ten microliters of 
these samples were separated on 10% SDS-PAGE under reducing condition, and 
transferred to a PVDF membrane. The membrane was visualized by Western blotting 
using NZ-1 as described IDH1-FLAG-PA12. Intensity of mNrp1ec-PA12 was quantified 
by densitometric analysis using ImageJ (Schneider et al. 2012). 
Expression and purification of HSA 
For the purification of soluble PA12-HSA and HSA-PA12 secreted from 
mammalian cells, HEK293T cells plated in a 15-cm culture dish were transiently 
transfected with the plasmid using Polyethylenimine (Sigma-Aldrich), and the culture 
supernatant was harvested ~72 h after the transfection. These purifications were 
performed as described mNrp1ec-PA12. 
Screening of NZ-1-Sepharose regeneration condition 
These experiments were performed using BIACORE 2000 instrument. CM5 
sensor chip were immobilized with NZ-1 as described in binding kinetics analysis. For 
scouting the condition for the mild dissociation of antigen, the NZ-1 surface was first 
injected with a 100 nM solution of T4L-PA12 to saturate binding sites, incubated with 
PBST for 200 s to allow free dissociation, followed by an injection of various buffers 
for 30 s. Dissociation efficiencies were calculated by the ratio of the binding signal (in 
RU) before and after the injection of each solution (Fig. I-3).  
Figure I-3. SPR screening for the buffer condition suitable for the NZ-1 column 
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regeneration. Sensorchip surface immobilized with NZ-1 IgG was first infused with 100 nM 
T4L-PA12 for 60 s, allowed to spontaneously dissociate in PBST (pH 6.0) for 210 s, then 
treated with various test buffers for 30 s. Amount of T4L-PA12 remaining after the treatment 
was used to calculate dissociation efficiency shown in the Table I-2. Representative curves for 
the treatment with TBS, pH 7.5 (green) and Gly-HCl, pH 2.0 (magenta) are shown. 
Examination of NZ-1-Sepharose regeneration 
GFPUV-PA12 was expressed in transformed E. coli BL21 (DE3) cultured at 
37 °C in liquid LB medium containing 50 g/ml ampicillin until OD600 (Optical Density 
at 600 nm) was reached to ~0.6. GFPUV-PA12 expression was induced by the culture for 
~24 h at 16 °C in the presence of 1 mM IPTG. Culture medium was centrifuged. The 
cells were suspended in TBS (pH 7.5) [20 mM Tris-HCl, 150 mM NaCl, 0.25 mM 
PMSF, 10 M Leupeptin, 1 M Pepstatin], and were sonicated. Then the suspension 
was centrifuged, and the soluble fraction (supernatant) was collected. The lysates were 
passed through a 0.45 m filter to remove impurities, and aliquots were stored at -80 °C 
until later use. Small-scale purification of GFPUV-PA12 was perfomed as follows. A 
mini column (Bio-Rad) containing 500 l of NZ-1-Sepharose was equilibrated in TBS. 
Bacterial lysate (250 l) was applied onto the column, followed by a washing step (2 ml 
of TBS) and an elution step (4 ml of 10 mM MES at pH 6.0 containing 3 M MgCl2, 500 
l × 8). No. 2-5 fractions were named as elution fraction, because there were many 
GFPUV proteins in these fractions. Used NZ-1-Sepharose was washed with TBS (pH 
7.5), and this NZ-1-Sepharose was reused the purification for GFPUV-PA12. The 
evaluation of NZ-1-Sepharose reuse times was performed with the repeat of this 
purification and regeneration cycle. The GFPUV-PA12 contained in the elution fraction 
obtained from each purification cycle was quantified with a fluorescence measurement 
at excitation and emission wavelengths of 390 and 513 nm, respectively, using a Hitachi 
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F-7000 fluorescence spectrophotometer (Hitachi). All chromatographic procedures were 
performed at 4 °C (Fig. I-4). 
Confirmation of used NZ-1-Sepharose regeneration 
NZ-1-Sepharose used for the purification of mNrp1ec-PA12 was incubated 
with × 10 column volume of 3 M MgCl2 in 10 mM MES (pH 6.0) at room temperature 
under gentle agitation, with varying time and buffer change frequency (10 min × 3, 10 
min × 6, 1 h × 1, 1 h × 3, over night × 1). After washing with TBS (pH 7.5) for 
removing MgCl2, all proteins remaining in the NZ-1-Sepharose were eluted by × 2 SDS 
Sample buffer [125 mM Tris-HCl (pH 6.8), 4% (w/v) SDS, 20% (w/v) glycerol, 0.01% 
(w/v) BPB]. These eluted proteins were subjected to 10% SDS-PAGE under reducing 
condition and stained with fluorescent dye (Oriole, Bio-Rad). 
Figure I-4. Repeated purification of GFPUV on NZ-1-Sepharose column for regeneration.
(A) Procedure for the regeneration cycle of NZ-1-Sepharose used PA-tagged GFPUV purification. 
(B) Fluorescent images of the NZ-1 column at each step. The column was illuminated by a 
hand-held illuminator emitting long wavelength (~365 nm) UV light. 
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Results 
Kinetic analysis of NZ-1/PA tag interaction 
Previous investigations by Y. Kato et al., have indicated that NZ-1 had been 
recognized by linear peptide derived from human podoplanin using ELISA 
(Enzyme-Linked ImmunoSorbent Assay) (Ogasawara et al. 2008). The construction of 
an excellent epitope tag system needs a high 1:1 binding affinity between tag and 
antibody. Although many anti-peptide antibodies bind to multiple peptide tag on a 
carrier protein with high affinity, the real affinity toward single peptide tag is often low. 
Such antibodies are not suitable for purification tag system, because they do not 
effectively capture the tagged proteins in solution, and requires too long capture time 
and too much the amount of resin. Therefore, I estimated the 1:1 real binding kinetics 
between NZ-1 and its antigenic peptide in solution. 
I evaluated binding kinetics between NZ-1 and its antigenic peptide and 
compared it with three other tag/mAb pairs that are commercially available as 
purification systems (FLAG tag system, HA tag system, Myc tag system) using BLI 
(Bio-Layer Interferometry). BLI is a technology for measuring the biomolecular 
interactions, observing the optical reflection of sensor surface immobilized the objective 
molecules. The interactions can be measured in real-time when white light was incident 
from inside sensor, because the interference pattern is shifted depending on the amount 
of molecules on the biosensor chip. Antibodies used were M2 (anti-FLAG, available 
from Sigma-Aldrich) (Brizzard et al. 1994), 4B2 (anti-Myc, available from WAKO Pure 
Chemical Industries Ltd.), and 9E10 (anti-Myc, available from WAKO Pure Chemical 
Industries Ltd.) (Chan et al. 1987). In order to make fair comparison, all peptide tags 
were fused to the same model protein T4 lysozyme (T4L) using identical length of 
linker (Fig. I-1). Then, the T4L was tagged either N- or C-terminal. Moreover, these 
T4L attached with various tags were purified by His tag and Ni-NTA agarose. These 
purified T4L mutants were high purity. The molecular weight of these T4L depended on 
the attached tag length (Fig. I-5), and it was confirmed that these T4L were 
monodisperse monomer state in solution using gel filtration chromatography (data not 
shown). Hereafter, I used these T4L mutants when I calculate the dissociation constant 
(KD value). 
BLI sensors were immobilized with each antibody using amine coupling 
method, and the binding affinity of each epitope tag system were estimated using this 
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sensors and the above T4L mutants. Although all anti-tag mAbs exhibited reasonably 
appropriate binding behavior toward each antigenic peptide in the biolayer 
interferography experiments using Octet devise (Fig. I-6), NZ-1/PA tag interaction was 
exceptional in that it did not show dissociation over the assay time of few minutes (Fig. 
I-6A, B). In fact, curve fitting tagged C-terminally of each data derived exceptionally 
slow dissociation rate constant for NZ-1/PA interaction, resulting in much higher overall 
affinity than other tag systems (Fig. I-6C). Meanwhile, the T4L attached with PA tag at 
the N-terminal dissociated faster than the T4L attached with PA tag at the C-terminal, 
and the binding affinity between PA tag and NZ-1 decreased. However, all tagged T4L 
in this research had similar results, and it was suggested that the reason depended on not 
only the characteristics of interaction between tag and antibody, but also the 
characteristics of T4L. The very slow dissociation rate is a property highly desirable for 
isolation purpose, because it assures that tagged protein are completely captured and 
does not leak during the washing steps. 
Figure I-5. Purity check of the tagged T4L mutant proteins used for the binding assays.
T4L mutant proteins purified by Ni-NTA agarose were subjected to 15% SDS-PAGE under 
reducing condition and stained with CBB. 
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Figure I-6. Bio-layer interferometry kinetic analysis of various anti-epitope tag antibodies.
(A), (B) Representative BLI binding data for tagged T4L (A, N-terminal; B, C-terminal). Each 
anti-tag mAb was immobilized on sensor tips. Association (from 60 s to 120 s) and dissociation 
(from 120 s to 240 s) phases are shown for serial dilution series of the tagged T4L (red, 30 nM; 
blue, 10 nM; purple, 3 nM; green, 1 nM). Black lines represent a global fit of the data to a 1:1 
binding model. (C) Kinetic binding parameters of (B) for each interaction obtained using 
BIAevaluation. 
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Minimal sequence requirement for the PA tag 
 NZ-1 was raised against 14-residue peptide (EGGVAMPGAEDDVV; PA14) 
corresponding to residues 38-51 of human podoplanin (Kato et al. 2006). Previous study 
showed that the central 10-residue portion (GVAMPGAEDD; PA10) was indispensable 
for the recognition (Ogasawara et al. 2008). To decrease the effect on tagged proteins, 
epitope tag has a preference for a short amino acids sequence. Therefore, in order to 
determine the minimal peptide region that warrants observed high affinity, I carried out 
surface plasmon resonance (SPR) binding experiments between NZ-1 and various 
versions of PA tagged protein. 
As shown in Fig. I-7A and B, either PA14 or PA12 (GVAMPGAEDDVV) 
tags attached C-terminally to T4L bound to NZ-1 with high affinity in an 
indistinguishable manner, indicating that the N-terminal two residues (Glu-Gly) were 
dispensable. In contrast, PA10-tagged version showed greatly reduced affinity 
(~1/10,000) (Fig. I-7C), suggesting that the last two valines were important to ensure 
the high affinity. I next tested whether PA tag was compatible with N-terminal fusion. 
As shown in Fig. I-7D, E, and F, both PA14 and PA12 mediated high affinity binding to 
NZ-1 when appended at N-terminal of T4L, although the dissociation was slightly faster 
than the C-terminal versions. Interestingly, affinity of PA10-T4L was decreased by only 
1.5-fold from PA12 and PA14. It seems likely that the presence of the last two residues 
is important for the high affinity but they can be substituted by other amino acids (such 
as Arg-Glu in PA10-T4L). Hereafter, I will use PA12 sequence for all applications. 
To determine which amino acid residues within the PA12 are critical for the 
recognition by NZ-1, ten non-alanine residues were mutated to alanine and each mutant 
(in the format of T4L-PA12) was evaluated in SPR assay. As clearly shown in the 
overlaid sensorgrams in Fig. I-8, mutations at M4 and D10 had the most severe effect, 
indicating the major contribution of these residues in the binding. Effects of four other 
mutations (P5A, G6A, E8A, and D9A) were less pronounced, and the rest of the 
mutants exhibited virtually identical binding behavior to the original PA tag. Therefore, 
NZ-1 seems to achieve the very high affinity toward PA tag using a combination of 
many interactions to the central core segment (M4-D10), with the contribution of M4 
and D10 being dominant. 
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Figure I-7. Surface plasmon resonance kinetic analysis of NZ-1 binding toward various PA 
tags. Serially diluted PA-tagged T4L proteins (3.125, 6.25, 12.5 and 25 nM) were injected over 
the CM5 sensor chip immobilized with NZ-1 for 60 s, followed by dissociation in PBST for 120 
s at a flow rate of 20 l/min. PA14 (A, D), PA12 (B, E), or PA10 (C, F) peptides were fused 
either C-terminally (A-C) or N-terminally (D-F) to T4L protein. Each set of binding curves was 
globally fitted to 1:1 binding model to derive dissociation equilibrium constant (KD) values 
shown in the boxes. 
Figure I-8. Effect of alanine substitutions of PA tag sequence on the binding to NZ-1 using 
SPR. Purified alanine-substituted versions of T4L-PA12 diluted at 20 nM were injected over the 
surface immobilized with NZ-1 as described in the legend to Fig. I-7 and sensorgrams after 
subtraction of the buffer control were overlaid. 
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Utility of NZ-1 as a detection antibody 
 It is expected that NZ-1 and PA tag can be used as a protein specific detection 
system, because they had very high affinity and specificity. To test this idea, a 
cytoplasmic enzyme isocitrate dehydrogenase 1 (IDH1) was doubly tagged with FLAG 
and PA (IDH1-FLAG-PA12) (Fig. I-1), and expressed in human osteosarcoma cell line 
U-2 OS that expresses low endogenous podoplanin (obtained from Prof. Y. Kato) (Kato 
Kaneko et al. 2014). As shown in Fig. I-9A, left lane, Western blotting of the resultant 
cell lysate with NZ-1 produced a strong band corresponding to the expressed IDH1 (~45 
kDa). The same membrane as above stained by CBB visualized many bands, however, 
IDH1 was not shown in Fig. I-9A, right lane. It is suggested that NZ-1 was able to 
detect the IDH1 with high sensitivity. NZ-1 immunoblot of the untransfected cells did 
not show any reactive bands (data not shown), indicating very high specificity of the 
detection. In contrast, a number of nonspecific bands other than tagged IDH1 were seen 
in the anti-FLAG M2 antibody immunoblot (Fig. I-9A, middle lane). In addition to the 
high specificity, detection by NZ-1 was proven highly sensitive, because the signal 
intensity of the reactive band was saturated after incubating with NZ-1 for as short as 5 
min (Fig. I-9B), and at concentration as low as 0.1 µg/ml (Fig. I-9C). Therefore, PA 
tag/NZ-1 system was proved that this is extremely useful system. 
 Next, I applied NZ-1/PA tag combination to the flow cytometric analysis of 
cell surface receptors. An expression construct for a type I transmembrane protein rat 
neuropilin-2 (rNrp2) was engineered to carry PA tag at its N-terminal (extracellular 
domain) and mCherry at its C-terminal (cytoplasmic domain) (PA12-rNrp2-mCherry) 
(Fig. I-1), and was transiently transfected into CHO-K1 cells. Inspection of cells by 
fluorescence microscopy after transfection indicated that ~20% cells were positive for 
the Nrp2-mCherry (Fig. I-10A). Similar level of surface expression was confirmed by 
the flow cytometric analysis of the same cells with NZ-1 (Fig. I-10B, solid line 
histogram). Furthermore, efficient staining was achieved even when the concentration 
of the primary antibody was reduced to 0.1 µg/ml NZ-1 (Fig. I-10B, inset), again 
underscoring the great potential of PA tag as a detection system. Therefore, it was 
suggested that the flowcytometry using NZ-1 was able to detect and quantify the 
membrane protein attached with PA tag at the extracellular regions with high sensitively 
and simply. 
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Figure I-9. Western blot analysis of PA tagged IDH1 with NZ-1. (A) Total cell lysates from 
human osteosarcoma cells expressing the IDH1-FLAG-PA12 were electrophoresed under 
reducing conditions using 10% SDS-PAGE gel and transferred to a membrane. Three strips of 
the membrane containing the same amount of lysate were immunoblotted with NZ-1 (left), M2 
(center), or directly stained with CBB (right). The same membrane strips were used to assess the 
time course (B) or dose-dependency (C) of the NZ-1 incubation. In (B), membranes were 
incubated with 1 g/ml NZ-1 for the incubated period. In (C), membranes were incubated with 
varying concentrations of NZ-1 for 30 min. All steps after the NZ-1 incubation, including 
secondary antibody reaction and chemiluminescence visualization, were conducted under the 
exactly same condition for all membranes. 
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Figure I-10. Flow cytometric analysis of PA-tagged membrane protein. (A) Photographs of 
CHO-K1 cells transiently transfected with PA12-rNrp2-mCherry. Note that about 20% of the 
total cells express PA12-rNrp2-mCherry (magenta). (B) Untransfected CHO-K1 cells (gray 
area) or CHO-K1 cells transiently transfected with PA12-rNrp2-mCherry (solid line) were 
incubated with 10 g/ml NZ-1 and stained with FITC-labeled secondary antibody specific for 
rat IgG. Less than 1% of parental CHO-K1 cell population was positive with NZ-1 (region 
indicated by a bracket). Staining efficiency was expressed as the % positive cells and plotted 
against the concentration of primary antibody (inset). 
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Protein purification using NZ-1 and PA tag 
I next explored the possibility to apply NZ-1/PA tag interaction in a protein 
purification system. The resin immobilized with an antibody is usually used for the 
epitope tag purification. The flow of protein purification is (1) the tagged target proteins 
are captured by the resin immobilized with an antibody, (2) the resin is washed for 
removing the impurities, (3) only the target proteins is eluted from the resin. Many 
epitope tag systems are compatible with the competitive elution of the tagged protein by 
free antigen peptide. There are many advantages that it is possible to purify in the 
neutral condition, the detailed consideration of conditions is unnecessary, and the 
purification efficiency is high. In fact, various free antigen peptides for elution against 
various tags have been sold by company. Although the complex of tagged molecules 
and antibodies seems a stable structure, the interaction is repeated the association and 
dissociation. The reason why the target proteins can be eluted from an antibody resin by 
free antigen peptide is that free antigen peptide can inhibit the binding by very fast 
diffusion rate. Therefore, it was unclear whether PA tag/ NZ-1 system with very slow 
dissociation rate is possible to elute the target proteins as described above. I focused on 
the purification of recombinant proteins secreted into culture media from transfected 
mammalian cells, because such project generally suffers from the lack of robust 
purification method due to the low abundance of the protein in the starting material (i.e., 
culture supernatants). First, I used ectodomain fragment of mouse neuropilin-1 (mNrp1) 
as model protein. Although Nrp1 is membrane protein, I used soluble ectodomain 
fragment of mouse Nrp1 tagged C-terminally with PA12 (mNrp1ec-PA12, Fig. I-1). For 
the purification of mNrp1ec-PA12 from mammalian cells, HEK293T cells were 
transiently transfected, and the culture supernatant was harvested. Although there were 
many proteins derived from FCS in the supernatant, the mNrp1ec band was not 
visualized by SDS-PAGE (Fig. I-11A, c. sup). The electrophoresis image of 
flowthrough (through the NZ-1-Sepharose) was similar to c. sup (Fig. I-11A, 
flowthrough). However, the near-perfect capture of tagged protein during the affinity 
chromatography was confirmed by the presence of less than 5% antigen in the 
flowthrough fraction (Fig. I-11B). The captured mNrp1ec-PA12 did not dissociate in 
wash with × 20 column volume of wash buffer (4 column × 5) (Fig. I-11A, wash 1-5), 
and eluted from the resin by a solution containing 0.1 mg/ml PA14 peptide (Fig. I-11A, 
elution 7-11). The ability of free peptide to competitively elute bound antigen was rather
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Figure I-11. One-step purification of PA12-tagged proteins. (A) Purification of soluble 
ectodomain fragment of mouse neuropilin-1. Five microliters of the culture supernatant from 
the transfected cells before (c. sup) and after (flowthrough) NZ-1-Sepharose capture, as well as 
10 l of the five wash (lane 1-5) and ten peptide-elution fractions (lane 6-15) during the column 
chromatography were subjected to 10% SDS-PAGE under reducing condition and stained with 
CBB. (B) The culture supernatant and the flowthrough fractions from the chromatography 
shown in (A) were diluted with TBS as indicated and subjected to Western blotting using NZ-1. 
Intensity of the 120-kDa band was quantified by densitometric analysis and, shown below each 
lane. (C) One step purification of secretory protein human serum albumin (left, PA12-HSA; 
right, HSA-PA12). Five microliters of c. sup and flowthrough, as well as the 10 l of the wash 
and ten peptide-elution fractions during the column chromatography were subjected as 
described in (A). 
rather unexpected, because the interaction seemed to be almost irreversible in the 
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kinetic binding assays shown in Fig. I-6 and I-7. In fact, I found it essential to perform 
the elution in a step-wise manner rather than under continuous flow, and allow ~5 min 
of dissociation time for each fraction. I confirmed that the elution efficiency from 
NZ-1-Sepharose decreased when I did not incubate for the elution (data not shown). 
Next, to determine the most suitable affinity purification condition, I evaluated the ratio 
of sample volume and NZ-1-Sepharose volume, the incubation time for capture, and the 
concentration of PA14 peptide for elution, respectively. As a result, it was suggested that 
the most suitable condition is 1/200~1/100 (v/v) (NZ-1-Sepharose volume), 1~2 h 
(incubation time), over 0.1 mg/ml (PA14 peptide concentration) (Fig. I-2, Table I-2). To 
confirm the versatility of this method, I constructed human serum albumin (HSA) 
attached with PA tag at the N- or C- terminal (PA12-HSA, HSA-PA12) (Fig. I-1). 
HEK293T cells were transiently transfected, and the culture supernatant was purified as 
described above. As a result, I was able to purify the extremely pure target proteins in 
both cases (Fig. I-11C). Based on this method, this laboratory have so far applied 
PA-tag/NZ-1 system to purify the soluble and membrane proteins having widely 
different molecular weight (from 15 to >300 kDa), where >95% purity was regularly 
attainable in one step by NZ-1-Sepharose chromatography. Therefore, it was indicated 
that NZ-1 and PA tag is able to construct the extremely versatile protein purification 
system. 
Table I-2. Purification condition screening 
Resin vol. Incubation time    Elution buffer         Protein yeild 
1/100   2 h  0.1 mg/ml PA14 peptide    71.1 g 
1/400   2 h  0.1 mg/ml PA14 peptide    23.8 g 
1/200   2 h  0.1 mg/ml PA14 peptide    36.1 g 
1/50   2 h  0.1 mg/ml PA14 peptide    72.7 g 
1/100   15 min  0.1 mg/ml PA14 peptide    55.0 g 
1/100   30 min  0.1 mg/ml PA14 peptide    60.2 g 
1/100   1 h  0.1 mg/ml PA14 peptide    79.7 g 
1/100   2 h  0.05 mg/ml PA14 peptide    61.2 g 
1/100   2 h  0.075 mg/ml PA14 peptide    78.2 g 
1/100   2 h  0.2 mg/ml PA14 peptide    72.5 g 
1/100   2 h  2 M MgCl2 (pH 6.0)      72.0 g 
1/100   2 h  3 M MgCl2 (pH 6.0)      79.8 g 
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Reusability of the NZ-1-Sepharose 
In general, antibody-based purification systems tend to be costly compared to 
other methods that use affinity resins with immobilized chemical compounds (Lichty et 
al. 2005). Although the major reason for the high cost is the requirement of the use of 
synthetic peptide for the elution process, it is often noted that the limited reusability of 
the antibody resin is another cost-elevating factor. This is especially critical in an 
immunoaffinity system where the antibody binds its antigen tightly, because potentially 
damaging condition (e.g., high or low pH, denaturing agents, etc.) is required for the 
regeneration of the column to remove the peptide that was bound during the elution 
process. In fact, FLAG tag system that is representative of tag system decreases the 
purification ability for the antibody inactivated by the regeneration cycles, because the 
regeneration condition of M2 immobilized resin is acidic buffer at pH 3.0. I therefore 
sought to find conditions that can completely disrupt NZ-1/PA tag interaction while 
maintaining the functional integrity of the antibody. To this end, NZ-1 was covalently 
immobilized on a BIACORE sensorchip and allowed to saturate with T4L-PA12, 
followed by an injection of various buffers (Fig. I-3). Table I-3 shows the effect of brief 
(30 sec) exposure to a variety of conditions on the dissociation of the bound antigen. 
Unlike some polyol-sensitive antibodies (Burgess and Thompson 2002; Nogi et al. 
2008), inclusion of water-miscible organic solvent such as propylene glycol did not 
have dissociating effects. Strongly acidic condition (pH 2.0) was effective in disrupting 
the interaction (Table I-3), but it severely damaged the NZ-1 itself, because the surface 
lost binding ability (data not shown). Lowering the pH of the buffer was generally 
effective, especially when high concentration of salt was included. I examined the 
various pH buffer (pH 4~7) with high concentration of various salt (NaCl, NaBr, 
MgCl2). After testing several combinations, I found that a slightly acidic (i.e., pH 6.0) 
buffer containing 3M MgCl2 could completely remove bound antigen from the antibody 
(Table I-3). It was confirmed that brief injection of this buffer onto the NZ-1 surface did 
not affect the binding capacity (data not shown). 
I adopted the above buffer as a column-regeneration condition after each 
cycle of protein purification using NZ-1-Sepharose. In order to assess potential 
damaging effect of the regeneration condition, GFPUV-PA12 expressed in bacterial 
cytosol was used as a test protein (Fig. I-1) and repeated 
absorption-elution-regeneration cycles were performed on a small column of 
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NZ-1-Sepharose (Fig. I-4). The quantity of GFPUV was simply estimated by 
measurement of fluorescence. Surprisingly, the NZ-1 column could withstand 60 times 
of regeneration cycles, as evidenced by the sustained recovery of the GFPUV-PA12 in 
each eluted fraction (Fig. I-12). This result indicated that the NZ-1-Sepharose was able 
to be efficiently regenerated by the treatment with 3M MgCl2 at pH 6.0 without causing 
any damage on the immobilized antibody. Additionally, the elution of the target proteins 
from NZ-1-Sepharose was able to be used not only high-cost synthetic peptide but also 
low-cost buffer, 3 M MgCl2 at pH 6.0 (however, the function of the target proteins must 
not affect in this condition). In fact, I attempted to purify mNrp1ec-PA12 using the 
elution buffer of 3 M MgCl2 at pH 6.0. As a result, the quantity of the purified protein 
was similar to one eluted by PA14 peptide (Table I-2). It is therefore clear that the 
PA-tagged proteins can be eluted from NZ-1-Sepharose by the treatment with PA14 
peptide or 3M MgCl2 at pH 6.0. 
Table I-3. Effect of various buffers on the interaction between PA tag and NZ-1  
Salt, additive pH (buffer) Dissociation efficiency (%) 
0.15 M NaCl 7.5 (Tris)             0 
no 2.0 (Gly-HCl)            91 
0.15 M NaCl 
+ 40% propylene glycol 
7.5 (Tris)             8 
2M NaCl 7.0 (PIPES)            28 
 6.0 (MES)            30 
 5.0 (Acetate)            40 
 4.0(Acetate)            87 
2M NaBr 7.0 (PIPES)            52 
 6.0 (MES)            59 
 5.0 (Acetate)            77 
 4.0(Acetate)            97* 
2M MgCl2 7.0 (PIPES)            93 
 6.0 (MES)            94 
 5.0 (Acetate)            96* 
 4.0(Acetate)            98* 
3M MgCl2 6.0 (MES)            98* 
* Conditions suitable for antigen elution 
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Figure I-12. Effect of the repeated column regeneration treatments on the yield of 
PA-tagged GFPUV purification by NZ-1-Sepharose. Repeated column purification of GFPUV
was performed as described in Fig. I-4. The graph shows the amount of GFPUV-PA12 contained 
in the pooled eluate fraction from each purification cycle quantified with a fluorescence 
measurement. 
Although NZ-1-Sepharose can be regenerated and reused as described above, 
there is the danger of cross-contamination when the different target protein is purified 
by used resin. Finally, I examined the detailed regeneration condition of 
NZ-1-Sepharose used for protein purification. NZ-1-Sepharose used for the purification 
of mNrp1ec-PA12 was incubated with × 10 column volume of 3 M MgCl2 (pH 6.0) at 
room temperature under gentle agitation, with varying time and buffer change 
frequency (10 min × 3, 10 min × 6, 1 h × 1, 1 h × 3, over night × 1). After washing the 
resin, all proteins remaining in the NZ-1-Sepharose were eluted by SDS. It was 
confirmed that mNrp1ec-PA12 remained very slightly into the resin in any conditions 
(Fig. I-13). However, the proteins detected in this experiment were soluble by SDS. It 
was proposed that the proteins were physically captured into resin by the degeneration 
and aggregation. Therefore, it is suggested that the danger of cross-contamination is not 
high when the proteins are eluted by mild condition such as free antigen peptide. Finally, 
it was revealed that the regeneration using 3 M MgCl2 at pH 6.0 is sufficiently the once 
treatment for 1 h, and it is not impossible to use the same resin for the purification of 
different proteins, in these experiments. 
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Figure I-13. Residual tagged proteins remaining inside the used NZ-1-Sepharose after the 
regeneration. NZ-1-Sepharose used in the experiment shown in Fig. I-11 (A) was incubated 
with x10 column volume of 3 M MgCl2 in 10 mM MES, pH 6.0 at room temperature under 
gentle agitation, with varying time and buffer change frequency (10 min x3, 10 min x6, 1 h x1, 
1 h x3, over night x1). After washing with TBS, all proteins remaining in the NZ-1-Sepharose 
were eluted by SDS. These eluted proteins were subjected to 10% SDS-PAGE under reducing 
condition and stained with fluorescent dye. Red arrow, mNrp1ec-PA12; blue arrows, NZ-1 
subunits. 
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Discussion 
In this research, I have successfully developed a novel affinity tagging system 
PA tag system by applying a unique monoclonal antibody NZ-1 against human 
podoplanin. Owing to its unusually high affinity toward linear dodecapeptide antigen, 
NZ-1 can be used to detect, capture, and purify tagged proteins in various assay formats. 
The most remarkable advantage of this system is the ability to purify low abundant 
proteins at high yield in one step, along with its extended reusability. Moreover, this 
system has several advantages. First, the advantage is the characteristics of PA tag 
amino acid sequence. PA tag consists of 12 amino acid residues of a relatively short 
length, and does not have large hydrophobic or basic amino acids. Therefore, it is 
suggested that PA tag has little effect on the tagged protein (e.g., expression level, 
localization, function). Second, the free antigen peptide (EGGVAMPGAEDDVV) of PA 
tag is easy to dissolve, and has a high yield in solid-phase peptide synthesis. Third, this 
peptide does not inhibit the measurement of protein concentration using absorption 
spectroscopy, because this sequence does not have aromatic amino acid. The fractions 
eluted by PA peptide can be easily monitored which fractions have the target protein by 
measurement of absorbance at 280 nm. Finally, it is also a valiant advantage that this 
system can be used as many protein detection tools (Western blotting (Fig. I-9), flow 
cytometry (Fig. I-10), immunocytochemistry (Kaneko et al. 2013a)). Particularly, in 
Western blotting, we have to consider the combination of host cell and tag (and 
antibody), because the non-specific bands derived from host cell may bear when the low 
expression level protein was visualized using anti-tag antibody by Western blotting. 
However, we dont have to consider as above when we use NZ-1 and PA tag. It is 
possible that this tag system can save the cost and time in all methods, because this 
system has affinity higher than the existing tag systems. 
On the other hand, PA tag system has also disadvantages. Since NZ-1 was 
established for antibody toward human podoplanin, NZ-1 specifically binds to human 
podoplanin (and monkey podoplanin that has the same sequence in PLAG domain). 
Among commonly used cell lines, HEK cells and COS cells have been confirmed the 
positive reaction for NZ-1 staining. In fact, I confirmed that the signals derived from 
endogeneous podoplanin in these cell lines were detected in flow cytometry and 
Western blotting (data not shown). However, it was revealed that PA tag system was 
able to be used for the purification of soluble proteins in these cell lines (Fig. I-11), 
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because podoplanin is membrane proteins. Additionally, these cell lines can be used as 
expression hosts if the purpose is to purify PA-tagged recombinant membrane proteins, 
because the contamination of endogenous podoplanin is negligible (Fujii et al. 2014). It 
was tested if PA tag system is compatible with the purification of membrane proteins. 
HEK293S GnT1- cells were transfected with N-terminally PA-tagged human EGFR. 
Next, PA-tagged EGFR was captured by NZ-1-Sepharose and eluted efficiently with 0.1 
mg/ml PA14 peptide solution. A great separation power of the PA tag/NZ-1 system is 
demonstrated by the successful purification of the 145 kDa EGFR protein from the low 
abundance cell lysate, with virtually no contaminations. Surprisingly, podoplanin (~37 
kDa) was not co-purified with the PA-tagged proteins even though the cell line 
expresses endogenous human podoplanin. It was reported that podoplanin was attached 
O-linked glycan at 52nd threonine (...EDVVT52PGT...) just behind the sequence of PA 
tag (Kaneko et al. 2007). It is possible that the effective affinity of NZ-1 for the epitope 
region (PLAG domain) of native podoplanin is relatively low, probably due to the steric 
hindrance of the peptide sequence by the nearby glycan chains, resulting in the 
inefficient capture during the affinity chromatography. After all, we have to be careful 
of the endogenous podoplanin when we use PA tag/NZ-1 system. On the other hand, as 
a result of alanine scanning, the side chains of Met4 and Asp10 in PA tag was important 
for the NZ-1 interaction (Fig. I-8). The NZ-1-reactive sequence is unique to human 
podoplanin and both Met4 and Asp10 are absent in mouse, rat, hamster, or dog 
podoplanin (Fig. I-14), indicating that cell lines from these animals are compatible with 
this system. In fact, NZ-1 does not exhibit any binding toward CHO cells in flow 
cytometry (Fig. I-10) or in Western blotting (Kato et al. 2006). 
This laboratory has already succeeded in the purification of many membrane 
proteins using PA tag system, and this system was able to be used in the presence of 
detergents (data not shown). Moreover, it is suggested that PA tag system with high 
affinity is suitable for a proteomic interactome analyses, because such study requires 
extremely high affinity (or more accurately, slow dissociation) between the tagged bait 
and the capture device to withstand extensive washing to eliminate nonspecific binders. 
In screening research of the specific interaction molecule against target proteins, the 
beads immobilized with a bait protein via anti-tag antibody have to be washed carefully 
to decrease the false-positive hits derived from non-specific binding. In this case, 
although tandem affinity purification (TAP) using FLAG tag is the most popular method 
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(Ogawa et al. 2002; Rigaut et al. 1999), the overwashing facilitates the dissociation of 
the bait protein and may decrease the ratio of s/n. NZ-1 and PA tag is expected to 
maximize its ability in this application, because they have the dissociation rate much 
slower than FLAG/M2. 
Overall, it is anticipated that the PA tag system will be a unique and powerful 
addition to our list of experimental tools in the field of protein expression and 
purification. 
Figure I-14. Sequence alignment of podoplanin PLAG domain from various species.
Amino acid sequences are from human (AAM73655.1), mouse (NP_034459.2), rat 
(NP_062231.1), hamster (XP_005081155.1), and dog (NP_001003220.1) podoplanins. 
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Chapter III 
Introduction 
In Chapter II, I constructed a novel affinity tag system PA tag system with 
high affinity and specificity using anti human podoplanin antibody NZ-1, and it was 
revealed that this tag system proved to outperform many existing affinity tag systems 
owing to its high affinity, high selectivity, and extended reusability. If this tag system is 
used only as general affinity tag system, I might as well finish this research at this point. 
However, it is very useful for the understanding on the physicochemical foundation of 
the protein-protein interaction that the reasons of the superior interaction between PA 
tag and NZ-1 are explained. Additionally, to append the desirable advantages and 
overcome the disadvantages in this system using protein-engineering technology, I have 
to know the detailed structure. Then, to understand this structural basis, I determined the 
crystal structures of NZ-1 with bound PA peptide. As a result, it was indicated that NZ-1 
recognizes the hairpin turn of the middle of the PA tag sequence. This unique structure 
suggests that PA tag may be recognized by NZ-1 even if it is inserted into loop of a 
protein. Therefore, PA tag system may be able to be used as the system that the tag is 
able to be easily and generally inserted into the middle of a protein, as described 
Chapter I. 
In the latter half of this chapter, I examined whether it is possible as that PA 
tag can be inserted into a protein, using integrin IIb3 as a model protein. Integrin is a 
heterodimer type I transmembrane protein composed of  subunit and  subunit, and is 
a main cell adhesion receptor of multicellular animal. It was also known that integrin is 
dynamically changed the conformation from inactive state (bent conformation) to active 
state (extend conformation) (Luo et al. 2007; Springer and Dustin 2012; Takagi et al. 
2002b). The structure of the entire ectodomain IIb3 has been determined by X-ray 
crystallography (Zhu et al. 2008), and IIb3 has an antibody for evaluating the active 
conformation (Taub et al. 1989; Ginsberg et al. 1990). Therefore, I used IIb3 that has 
much information and many analysis tools, as a model protein. As a result of the 
examination of the PA tag insertion into various loops of IIb3  subunit, it was suggested 
that PA tag was able to be inserted into the middle of protein with the high affinity toward 
NZ-1. Moreover, it was revealed that NZ-1 physically induced the conformational 
change of the PA tag-inserted IIb3 from inactive form to active form by extending 
IIb3 conformation when the site of the PA tag insertion was selected. In this chapter, I 
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report the development of a novel technology that was impossible in the existing tag 
systems, using NZ-1 and PA tag. 
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Materials and methods 
Construction of expression vectors 
The ectodomain fragments of integrin IIb were designed as described for V3
previously (Takagi et al. 2002b). The complete ectodomains of IIb and 3 chains were 
fused at the C-terminal to leucine zipper peptide that is derived from GCN4. The 
peptide forms a disulfide-linked -helical coiled-coil to mimic the closely positioned 
and interacting the  and  subunit on the cell surface (Fig. II-1). This coiled-coil is 
called as velcro tag, and it induces the secretion of the stable integrin heterodimer in the 
culture supernatant (Oshea et al. 1993). The tag insertion into the ectodomain fragments 
of IIb chain was designed as shown in Fig. II-2. These mutants were named as follows 
by the domain name and the elements of secondary structure in the sites of tag insertion, 
W2_1, W2_2, W2_3, W2_4, W2_5, W1, Cap, W3, W6, Thigh F-G, Calf-1 X-Z, Calf-1 
E-F, Calf-2 X-Y, and Calf-2 F-G. For the construction of these mutants, DNA encoding 
these mutants were constructed by overlap-extension PCR and cloned into the plasmid 
vector of wildtype IIb chain. The primer list for this research was shown in Table II-1. 
W2_1 is described as an example, first the fragments were extended using the 
combinations of T7fwd and a2bW2PA_L1 (-), and a2bW2PA_U1 and a2bSP3 (-), 
respectively. Second, these fragments were extended using the combinations of T7fwd 
and a2bW2PA_L2 (-), and a2bW2PA_U2 and a2bSP3 (-), respectively. Finally, these 
fragments were overlapped using T7fwd and a2bSP3 (-), and the DNA fragment was 
cloned into SpeI-SbfI site of the template. The others were constructed as above. 
For the construction of full-length IIb and 3 subunit, the mutated regions of 
the soluble integrin were cloned into the vector as constructed previously (Luo et al. 
2005). After W1, Cap, W2_5, Thigh F-G, Calf-1 X-Z, Calf-1 E-F, Calf-2 X-Y were 
digested by restriction enzyme, these fragments were cloned into SpeI-SbfI site of the 
template. Only in Calf-2 F-G, the tag was inserted into the template by 
overlap-extension PCR. These fragments were extended using the combinations of 
a2bSP6 and a2bCalf2FGGPAL31_1 (-), and a2bCalf2FGPAU31 and Rev21, 
respectively. The first fragment was extended using the combinations of a2bSP6 and 
a2bcapPAL27_2 (-). Finally, these fragments were overlapped using a2bSP6 and Rev21, 
and the DNA fragment was cloned into SbfI-XbaI site of the template.  
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Figure II-1. Schematic representation of the integrin IIb3 used in Chapter II. Integrins are 
heterodimers of non-covalently associated  and  subunits. (A) Full length integrin IIb3. (B) 
Integrin IIb3 ectodomain with velcro tag. 
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Figure II-2. Amino acids sequences around the regions inserted with each tag used in 
Chapter II. Amino acid sequences of the artificially added tag and the linker segments are 
shown. Purple, PA tag sequences; blue, FLAG tag sequences; magenta, Myc tag sequences; 
cyan, loop sequences; black, secondary structure regions; italic, linker sequences. 
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Table II-1. Primer list
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Table II-1. Primer list (continued)
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Table II-1. Primer list (continued)
Antibodies used 
The rat anti-PA monoclonal antibody NZ-1 (IgG2a, ) and the 
FITC-conjugated NZ-1 was provided by Prof. Y. Kato as described in Chapter II. The 
mouse anti-velcro monoclonal antibody 2H11 was purified from the hybridoma (a gift 
from E. Reinhart) (Chang et al. 1994). The rabbit anti-velcro polyclonal antibody was 
conjugated the biotin using EZ-link Sulfo-NHS-LC-Biotin (Thermo Scientific). The 
mouse anti-3 monoclonal antibody AP3 was purified from the hybridoma obtained 
from ATCC (Newman et al. 1985; Kouns et al. 1990). The AP3 was conjugated the 
fluorescent dye using DyLight 680 NHS Ester (Thermo Scientific) (DyLight680-AP3). 
The mouse anti-3 monoclonal antibody 7E3 and the mouse anti-IIb monoclonal 
antibody 10E5 were purified from the hybridoma (a gift from B. S. Coller) (Coller 
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1985; Artoni et al. 2004; Coller et al. 1983). The FITC-conjugated mouse anti-IIb3
monoclonal antibody PAC-1 (FITC-PAC-1) was obtained from Becton, Dickinson and 
Company (Taub et al. 1989). The Alexa488-conjugated goat anti-mouse IgG polyclonal 
antibody (rat absorbed) was obtained from Invitrogen. The PE-conjugated goat anti-rat 
IgG polyclonal antibody (mouse absorbed) was obtained from Southern Biotechnology. 
The anti-FLAG M2 and the anti-Myc 9E10 were used as described in Chapter II. 
Preparation of NZ-1 Fab 
Purified NZ-1 was dialyzed against PE buffer (pH 7.0) [20 mM Na/K 
phosphate, 10 mM EDTA]. The NZ-1 was digested by Immobilized Papain (Thermo 
Scientific) (2.2 mg IgG/0.2 ml resin) in the presence of 25 mM Cys-HCl (pH 7.0), and 
incubated for ~4 h at 37 °C under gentle agitation. Immobilized Papain was removed 
from the solution through the mini column, and the resin was washed twice (1 column × 
2) with PE buffer for collection of the antibody solution. The collected antibody 
solution was dialyzed against TBS (pH 8.0) [50 mM Tris-HCl, 150 mM NaCl], and the 
solution was slowly added to PA14 peptide-Sepharose (the resin immobilized with 
PA14 peptide ~5 mg/ml). The PA14 peptide-Separose was washed nine times (1 column 
× 9) with TBS (pH 8.0), and eluted eight times (1 column × 8) with 10 mM MES (pH 
6.0), 3 M MgCl2. After each fraction was monitored which fractions have NZ-1 Fab by 
measurement of absorbance at 280 nm, all fractions with NZ-1 Fab were collected and 
dialyzed against TBS (pH 7.5) [20 mM Tris-HCl, 150 mM NaCl]. The Fab solution was 
concentrated by ultrafiltration using Spin-X UF (MWCO [molecular weight 
cut-off] :10,000) (Corning), and purified by gel filtration chromatography using 
AKTAprime (GE Healthcare) on a Superdex 200 16/60 column equilibrated with TBS 
(pH 7.5), at a flow rate of 0.7 ml/min. Elution fractions were subjected to 12.5% 
SDS-PAGE and stained with CBB, No. 18-28 fractions with Fab were collected (Fig. 
II-3). The collected fractions were dialyzed against TBS (pH 7.5) [10 mM Tris-HCl, 50 
mM NaCl]. Finally, the Fab solution was concentrated to ~10 mg/ml by ultrafiltration 
using Spin-X UF (MWCO :10,000). 
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Figure II-3. Purification of NZ-1 Fab using gel filtration chromatography. (A) Gel filtration 
chart. NZ-1 Fab was purified on a Superdex 200 column equilibrated with TBS, at a flow rate of 
0.7 ml/min. (B) Elution fractions of purple arrows in (A) were subjected to 12.5% SDS-PAGE 
under reducing and non-reducing condition and stained with CBB. Red arrow, NZ-1 heavy and 
light chains (indistinguishable because they co-migrate); blue arrow, NZ-1 Fab fragment. 
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Structural analysis of NZ-1 with and without bound PA peptide 
To make a co-crystal of NZ-1 Fab and the antigen, PA14 peptide was 
dissolved in TBS (pH 7.5) [10 mM Tris-HCl, 50 mM NaCl], and added at 
approximately 3-fold molar excess to the concentrated NZ-1 Fab. Initial screening of 
crystallization conditions of the NZ-1 Fab/PA14 peptide (complex) and the ligand free 
NZ-1 Fab (apo) was carried out using Crystal Screen 1 and Crystal Screen 2 (Hampton 
Research) by the hanging drop vapor-diffusion. As a result, both of the proteins 
crystallized in many conditions. Initial crystallization condition was further optimized 
by the change of the precipitant (concentrations and kinds), the buffer (pH and kinds), 
and the salt (concentrations and kinds). As a result, the apo crystal was grown under the 
condition of 0.1 M sodium citrate buffer pH 5.6 and 12 or 15% (w/v) PEG4000, and the 
co-crystal was grown under the condition of 0.1 M sodium citrate buffer pH 5.6 and 
24% (w/v) PEG4000. These crystals were moved into the cryoprotectant solution [apo; 
0.1 M sodium citrate buffer pH 5.6, 12 or 15% (w/v) PEG4000, 10% (v/v) glycerol, 
complex; 0.1 M sodium citrate buffer pH 5.6, 24% (w/v) PEG4000, 10% (v/v) ethylene 
glycol] by the nylon loops (Hampton Research). Then, these crystals were frozen in 
liquid nitrogen. One of X-ray diffraction data sets of the apo crystal was collected at the 
beam line BL17A of Photon Factory, and another data set of the apo crystal was 
collected at the Taiwan beam line BL15A1 of NSRRC. The apo crystal data were 
processed using HKL2000 program package (Otwinowski and Minor 1997). As a result, 
the data set collected at NSRRC had high resolution, however, it did not have sufficient 
number of reflections at low-angle. Since these data sets collected at Photon Factory 
and NSRRC have the same crystal system (Table II-2), these data was processed using 
HKL2000 program package together. Initial phase was determined by molecular 
replacement method using Phaser-MR (McCoy et al. 2007). A rat anti-NGF AD11 
antibody Fab (IgG2a) structure (PDB ID; 1ZAN) was used as a search model for the 
ligand free NZ-1 Fab structure. The co-crystal X-ray diffraction data set was collected at 
the beam line BL1A of Photon Factory. The co-crystal data were processed using XDS 
program package (Kabsch 2010). Initial phase was determined by molecular 
replacement method using Phaser-MR. The apo structure was used as a search model 
for the NZ-1 Fab/PA14 peptide complex structure. The structure models were built 
using COOT (Emsley et al. 2010) with model refinement cycle with REFMAC5 
(Murshudov et al. 1997). Finally, many rounds of model-correction and refinement 
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resulted in a R-factor of 17.3% and a free R-factor of 20.9% in the apo form, and a 
R-factor of 18.3% and a free R-factor of 22.1% in the complex form. The structure 
models were validated using the program MOLPROBITY (Chen et al. 2010). Data 
collection and refinement statistics were listed in Table II-2. The interaction between 
PA14 peptide and NZ-1 Fab was calculated using the program LIGPLOT (Wallace et al. 
1995). All structure figures were prepared with the program PyMol (Schrödinger, LLC). 
Table II-2. Data collection and refinement statistics 
Values in parentheses correspond to the highest resolution shell. 
 complex apo (A) apo (B) 
Data collection 
Wavelength [Å] 0.9800 0.9800 1.0000 
Space group P21 P1 P1 
Unit Cell Parameters 
a=42.1 Å, b=79.8 Å, 
c=132.3 Å 
a=42.9 Å, b=57.2 Å, 
c=101.5 Å 
a=42.7 Å, b=57.1 Å,
c=101.0 Å 
=96.6° =97.9°, =101.5°, 
g=105.4° 
=97.8°, =101.5 °, 
g=105.7° 
Resolution [Å] 1.70 (1.75-1.70) 1.65 (1.70-1.65) 
Completeness [%] 98.4 (96.0) 98.5 (95.8) 
Rsym [%]a 5.3 (53.8) 12.9 (50.7) 
I/(I) 22.7 (3.7) 50.8 (3.7) 
Refinement 
Resolution range [Å] 39.92-1.70 97.42-1.65 
No. of atoms    
     Proteins 6377 6454 
     Ligands 171 0 
     Water molecules 611 676 
Rwork/Rfree (%)b 18.3/22.1 17.3/20.9 
RMSD bond length [Å] 0.011 0.010 
RMSD bond angle [°] 1.46 1.44 
a Rsym = 100 × |Ihkl  <Ihkl>| Ihkl, <Ihkl> is the mean value of Ihkl. 
b Rwork = 100 × ||Fo|  |Fc||/|Fo|. Rfree was calculated from the test set (5% of the total data). 
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Immunoprecipitation assay of the soluble IIb3
HEK293T were transiently transfected with the soluble tag-inserted IIb3. 
The medium of HEK293T cells incubated on the 6-well plate were changed to 
DMEM/5% FCS, and the cells were transfected with the soluble IIb subunit plasmid 
DNA (2 g) and the soluble 3 subunit plasmid DNA (2 g) using X-tremeGENE HP 
DNA Transfection Reagent. The culture supernatant was harvested ~72 h after the 
transfection, and was centrifuged. Each supernatant was mixed with 20 l of 
2H11-Sepharose (the resin immobilized with 2H11 ~2 mg IgG/ml) or NZ-1-Sepharose 
and incubated for ~2 h at 4 °C under gentle agitation. After the resin bound the soluble 
IIb3 was washed with TBS (pH 7.5) [20 mM Tris-HCl, 150 mM NaCl, 1 mM CaCl2, 1 
mM MgCl2] (800 l × 3), all proteins captured by the Sepharose were eluted by × 2 
SDS Sample buffer (25 l). These eluted proteins were subjected to 7.5% SDS-PAGE 
under reducing and non-reducing condition and stained with fluorescent dye (Oriole). 
The expression level was estimated by Western blotting using the 
immunoprecipitated proteins. The soluble tag-inserted IIb3 was expressed as described 
above. One milliliter of the culture supernatant was mixed with 20 l of Protein G 
Sepharose (GE Healthcare) and 2 g of various antibodies (anti-integrin 3 7E3, anti-PA 
NZ-1, anti-FLAG M2, anti-Myc 9E10), and incubated for ~2 h at 4 °C under gentle 
agitation, to capture IIb3 via an antibody. Next, Protein G Sepharose was washed with 
TBS (pH 7.5) (800 l × 3), and all proteins captured by the Sepharose were eluted by × 
2 SDS Sample buffer (25 l). These eluted proteins were separated on 7.5% SDS-PAGE 
and transferred to a PVDF membrane, followed by blocking with 5% skim milk in TBS 
(pH 8.0) with 0.05% Tween 20 for 60 min. For the primary antibody step, the 
membranes were incubated with 5 g/ml biotinylated anti-velcro polyclonal antibody 
diluted in TBS at pH 8.0, containing 0.05% Tween 20 and 1% BSA (TBST), for 60 min. 
For the secondary antibody step, membranes were incubated for 60 min with SA-HRP 
(VECTOR) diluted at 1:2,000 in TBST. Four consecutive washes (TBST, 5 min) were 
conducted between each step. The membranes were developed with ECL Prime 
reagent and analyzed using ImageQuant LAS 4000mini. 
Assessment of full-length integrin IIb3
Human podoplanin knockout HEK293T cells (PDIS-2) (a gift from Y. Kato) 
were transiently transfected with full-length integrin IIb3. The medium of PDIS-2 cells 
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incubated on the 6-well plate were changed to DMEM/5% FCS, and the cells were 
transfected with full-length IIb plasmid DNA (2 g) and full-length 3 plasmid DNA (2 
g) using X-tremeGENE HP DNA Transfection Reagent. After incubation for ~48 h at 
37 °C in 5% CO2, the cells were detached, washed twice with DMEM/10% FCS, and 
resuspended in 1 ml of Tyrodes buffer (pH 7.4) [137 mM NaCl, 12 mM NaHCO3, 2.6 
mM KCl, 5 mM HEPES, 2 mM CaCl2, 2 mM MgCl2, 1 mg/ml BSA, 1 mg/ml dextrose]. 
In the examination of expression level and recognition toward NZ-1, the cells were 
incubated with Tyrodes buffer containing 10E5 (1 g/ml) and NZ-1 (0.5 g/ml) for 30 
min at 20 °C, washed twice with Tyrodes buffer, and resuspended in Tyrodes buffer 
containing Alexa488-conjugated goat anti-mouse IgG polyclonal antibody (rat 
absorbed) diluted at 1:400 and PE-conjugated goat anti-rat IgG polyclonal antibody 
(mouse absorbed) diluted at 1:1,000. After incubation for 30 min at 20 °C, the cells 
were washed once and resuspended in Tyrodes buffer. In the assay for ligand binding of 
integrin IIb3, the cells were incubated for 10 min at 37 °C with or without 15 mM 
dithiothreitol (DTT).  Integrin IIb3 has been reported that the conformation was 
changed from inactive state to active state by DTT (Takagi et al. 2002b; Yan and Smith 
2001). After washing twice with Tyrodes buffer, the cells were incubated with Tyrodes 
buffer containing FITC-PAC-1 diluted at 1:20 and DyLight680-AP3 diluted at 1:50 for 
30 min at 20 °C, washed once with Tyrodes buffer, and resuspended in Tyrodes buffer. 
Finally, these cells were analyzed for the measurement of their fluorescent intensity by 
flow cytometer EC800 system (SONY) (Alexa488 and FITC were measured using 488 
nm laser and 525 nm filter, PE was measured using 488 nm laser and 595 nm filter, and 
DyLight680 was measured using 642 nm laser and 720 nm filter). The evaluation of the 
recognition toward NZ-1 was analyzed on the 10E5 positive cell population, and the 
assay for ligand binding was analyzed on the AP3 positive cell population. The 10E5 
(anti-IIb antibody) and 7E3 (anti-3 antibody) can be used as the marker of the IIb3
positive cells, because HEK cell line does not express the endogenous IIb and 3, and  
chain and  chain of integrin can not be expressed on the cell surface by themselves. All 
figures and the calculations of Mean. Fluorescent Intensity (MFI) were prepared with 
the program FlowJo (Digital Biology). 
Activation of full-length IIb3 by NZ-1 
The recognition of NZ-1 depending on the site of the PA tag insertion was 
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examined as described below. The PDIS-2 cells were transiently transfected with 
full-length integrin IIb3 inserted PA tag as described above, and the cells were 
incubated for 30 min at 20 °C in three different conditions (1. DyLight680-AP3 (1/50); 
2. DyLight680-AP3 (1/50), FITC-NZ-1 (0.5 g/ml); 3. DyLight680-AP3 (1/50), 
FITC-NZ-1 (0.5 g/ml), 0.5 mM MnCl2, 1 mM RGD peptide (GRGDSPK, 
Sigma-Aldrich)). The cells were washed twice with Tyrodes buffer, and analyzed by 
EC800 system. The activation of PA tag-inserted IIb3 using NZ-1 was estimated as 
described below. The cells were incubated with Tyrodes buffer containing 
DyLight680-AP3 diluted at 1:50 and FITC-PAC-1 diluted at 1:20 for 30 min at 20 °C, 
and with or without 10 g/ml NZ-1. Finally, these cells were washed twice with 
Tyrodes buffer, and were analyzed the recognition of PAC-1 by EC800 system. 
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Results 
Structural analysis of NZ-1 
In chapter II, it was suggested that the sequence of Met4-Asp10 in PA tag was 
the central core segment for the recognition toward NZ-1. However, this result was 
based on alanine scanning, and the detailed information of the binding mechanism 
between this polypeptide and NZ-1 was not known. To reveal this binding mechanism 
with the high specificity and affinity, and improve PA tag system, this binding 
mechanism has to be understood at the atomic resolution level. Therefore, I attempted to 
determine the crystal structure of NZ-1 with or without bound antigen peptide. As a 
result of the crystallization of NZ-1 Fab fragment with or without PA14 peptide 
(EGGVAMPGAEDDVV), each single-crystal was grown under the slightly different 
conditions. The suitable X-ray diffraction data sets were collected in the Synchrotron 
Radiation Facility using these crystals, and the complex structure gave 1.70 Å 
resolution diffraction and the apo structure gave 1.65 Å resolution diffraction (Table 
II-2). 
Next, I describe about these obtained structures. Both of the crystals (complex 
and apo) contain two copies of molecules in the asymmetric unit (Fig. II-4), and I 
obtained the two types of structure in each crystal. However, there are differences 
between these structure, the main difference is the angles between the VH-VL region (i.e., 
FV region) and CH1-CL region (called elbow angle) (Fig. II-5). When the FV regions 
(Heavy chain; E20-A137, Light chain; Q20-Q130) that are important for antigen 
binding were compared, the two molecules of the complex structure are 
indistinguishable with 0.237 Å RMSD (root mean square deviation), and that of the apo 
structure are indistinguishable with 0.123 Å RMSD. Therefore, there is no major 
structural difference between the two molecules. When the complex structure were 
compared with the apo structure, the conformation of NZ-1 Fv region was similar 
between the apo and the complex versions, with RMSD of 0.466 Å. Furthermore, these 
structures are essentially identical at the level of the side chains, even in the CDR 
(complementarily determining region) (Fig. II-6). I will discuss the minor difference of 
these structures with or without bound antigen in Discussion. Hereafter, I only discuss 
about complex structure in this section. 
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Figure II-4. Crystallographic asymmetric unit for the NZ-1 Fab with or without bound 
PA14 peptide. Two NZ-1 Fab molecules representing the asymmetric unit are shown in a 
cartoon model. Crystals of the ligand free NZ-1 Fab (A) and the NZ-1 Fab/PA14 peptide 
complex (B) had a space group of P1 and P21, respectively. Two molecules are colored 
differently (green for molecule-1 and cyan for molecule-2). Unit cells are also shown. 
Figure II-5. Structure of the NZ-1 Fab. Ligand free (left) and PA14-bound (right) states of 
NZ-1 Fab are shown as C ribbons, with molecules-1 and 2 colored in green and cyan, 
respectively. In both cases, two molecules are superposed at the Fv region corresponding to the 
heavy chain E20-A137 and light chain Q20-Q130, and viewed from the side to highlight the 
bending at the elbow (black arrow). 
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Figure II-6. Structural similarities between NZ-1 Fab with and without bound PA14 
peptide. Ligand free NZ-1 Fab molecule-1 (blue) and the NZ-1 Fab/PA14 peptide complex 
molecule-1 (red) are superposed at the Fv region. Residues that are either near the PA14 peptide 
(£4 Å) or involved in water-mediated hydrogen bond interactions to the peptide are shown in 
stick models. Bound peptide is removed for clarity. 
The peptide used for crystallization is PA14 peptide, and this peptide is 
2-residue longer in N-terminal than PA12 (GVAMPGAEDDVV) used as PA tag. In the 
complex structure, all region of PA12 (molecule-2) or 11-residue excepted Gly at the 
N-terminal (molecule-1) is clearly shown in the electron density of an antigen peptide 
(Fig. II-7), and the structure from Val2 to Val11 has no major structural difference 
between the two molecules in asymmetric unit. As shown in Fig. II-8A, the PA peptide 
is docked in the cleft formed between VH and VL of NZ-1, and the buried ASA (solvent 
accessible surface area) between the PA peptide and NZ-1 is calculated to be ~1,200 Å2. 
Within the binding pocket of NZ-1, the PA peptide assums a tight 2-residue type II 
-turn conformation, with Pro7 and Gly8 being the tip of the hairpin, and NZ-1 
recognizes the entire peptide with horseshoe shape centering on the hairpin (Fig. II-8A, 
B). This binding mode is different from the general binding mode that the extended 
peptide is recognized by anti-peptide antibody. There are a number of contacts between 
the peptide and the Fab, particularly at the region encompassing Met4-Asp10 (Fig. 
II-8C). The side chain of Met6 is deeply inserted into the cleft and makes many van der 
Waals interactions. The side chain of Asp12 is also inserted into the cleft and makes 
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multiple hydrogen bonds, with Gly52, Thr118, Ser119, and Arg120 within the Fab 
heavy chain via direct hydrogen bonds. In Chapter II, many amino acid residues 
(Met4-Asp10) were confirmed to be essential for the binding through a series of SPR 
binding assays in which ten non-alanine residues in PA peptide were mutated to alanine 
(Fig. I-8). Moreover, M4A and D10A mutations in the tag sequence nearly eliminated 
the binding toward NZ-1, indicating that these are the most important residues. 
Additionally, the main chain of Val2, Ala3, and Val11 interact with the Fab via direct 
hydrogen bond. It is suggested from these observations that at least 10-residue portion 
of the PA peptide (Val2-Val11) is required for the high affinity. 
Figure II-7. Electron density map of PA14 peptide. The weighted 2Fo-Fc electron density 
map (blue wireframe) is contoured at 1.0 . The NZ-1 Fab heavy chain, light chain and PA14 
peptide are shown in green, cyan and white, respectively. 
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As described in Chapter II, PA tag sequence is derived from human 
podoplanin PLAG domain. Human podoplanin is one of platelet aggregation factors on 
malignant cancer cells, and is implicated in tumor-induced platelet aggregation by 
binding to CLEC-2 on platelet surface. NZ-1 inhibits the binding of podoplanin to 
CLEC-2, and the platelet aggregation (Kato et al. 2008; Kato et al. 2006). Recently, M. 
Nagae et al., reported the complex structure of CLEC-2 and glycopeptide derived from 
human podoplanin (Nagae et al. 2014). In the report, the part of PA tag sequence is 
included in the peptide sequence recognized by CLEC-2, and amino acids equivalent to 
Glu8 and Asp9 are important for the binding (Fig. II-9A). Human podoplanin with 
bound NZ-1 does not bind to CLEC-2, because Glu8 and Asp9 are inside the binding 
pocket of NZ-1 when human podoplanin binds to NZ-1 (Fig. II-9B). Therefore, the 
reason why NZ-1 can inhibit the platelet aggregation was revealed. 
Figure II-8. Recognition mode of PA peptide by NZ-1 Fab. (A) Stereo view of the PA14 
peptide docked onto the binding site of the NZ-1 Fab. NZ-1 Fab structure is shown in a surface 
model, and PA14 peptide structure is shown in a stick model. The NZ-1 Fab heavy chain, light 
chain and PA14 peptide are shown in green, cyan and white, respectively. Main chain hydrogen 
bond maintaining the type II -turn is shown in yellow dotted line. (B) Structure of PA14 in (A). 
The length between Val2 C and Val12 C is measured using PyMol. (C) Residue-wise contacts 
between NZ-1 Fab (gray bonds) and PA14 peptide (purple bonds) analyzed by LIGPLOT 
program. Bond length cutoff is set to 3.35 Å for hydrogen bonds (denoted by green dotted line) 
and inter-atomic distance range of 2.9-3.9 Å is used for van der Waals contacts (orange eyelash). 
Oxygen, nitrogen, carbon, and water molecules were shown in red, blue, black, and cyan 
spheres. 
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Figure II-9. Crystal structure of CLEC-2/glycopeptide complex and NZ-1 Fab/PA14 
peptide complex. (A) Structure of CLEC-2/glycopeptide complex (PDB ID: 3WSR), with the 
CLEC-2 and glycopeptide is shown in surface and stick models, respectively. The carbohydrate 
moieties within the podoplanin glycopeptide are colored in yellow. Glu8 and Asp9 are 
highlighted in magenta. (B) Crystal structure of NZ-1 Fab/PA14 peptide complex as in Fig. 
II-8A but viewed from an orientation to highlight the position of the Glu8-Asp9 segment 
(magenta). 
Binding assay of NZ-1 and PA tag inserted into loop region 
As a result of structural analysis of the NZ-1/PA peptide complex, NZ-1 
recognizes the central part of PA tag with -turn, and both of N- and C-terminal in PA 
tag have projected outward from antibody (Fig. II-8A, B). This corresponds to the reslt 
that the amino acids of PA tag at the N- and C-terminal are not important for the binding, 
and it was suggested that PA tag can be recognized by NZ-1 even if it was inserted into 
the site of the restricted structure as a hairpin turn of a protein. To prove this hypothesis, 
I used IIb subunit of integrin IIb3 that consists of four -rich domains and has many 
-turns, as a model protein (Fig. II-10A). Integrin is a heterodimer transmembrane 
protein with  subunit and  subunit. To enable the exhaustive analysis for expression 
level of mutants, I used the soluble IIb3 that was removed a transmembrane domain of 
both subunits, and was attached with a disulfide-linked -helical coiled-coil (velcro tag) 
at the C-terminal. The mutated IIb subunit and 3 subunit were secreted in the culture 
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supernatant as a stable heterodimer, when the IIb and 3 chains were co-expressed. The 
expression level of the mutants was evaluated by anti-velcro antibody or anti-3
antibody (Fig. II-1). 
Figure II-10. Surface exposed loops in integrin IIb3 ectodomain selected for the tag 
insertion. (A) Crystal structure of IIb3 ectodomain (PDB ID: 3FCS) is shown in a cartoon 
model, with each -rich IIb structural domains (-propeller, Thigh, Calf-1, and Calf-2) labeled 
in red. The ten loop regions used for the tag insertion are shown in cyan and labeled with black 
letters. (B) Close-up view of the loop regions that were compatible with PA-tag insertion. Loops 
with good expression upon the tag insertion are colored in cyan, while that with low expression 
level are in yellow. 
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PA tag was inserted into the site of 3-4 loop region in W2 that belongs to 
seven blades of -propeller domain in  subunit (blade; it is described as W1-W7 
because it consists of 4-stranded -sheet). This region forms the turn of 5-residue 
(QPESG) including proline (Fig. II-10B). The end-to-end length of PA peptide in the 
complex structure (C length between Val2 and Val12) is 13.0 Å (Fig. II-8B), and the 
length at the base of the hairpin loop in W2 is 5.2 Å (Fig. II-10B). If PA tag was inserted 
into the site without linker sequence, the structure of PA tag might be destroyed. 
Therefore, to be made to have flexibility at the terminals of PA tag, I prepared several 
constructs with linker sequence of 2-4 residue (Fig. II-2A). Integrin is known as the 
extremely complex multidomain protein, and the expression of the heterodimer is 
inhibited by small structural imperfections (Takagi et al. 2002a). The structural 
imperfections of mutants were able to be estimated by the examination of expression 
and secretion in heterodimer. The resultant IIb3 ectodomain mutants were subjected to 
the immunoprecipitation with anti-velcro antibody, and the bands of integrin 
heterodimer in all mutants were similar to wildtype (Fig. II-11, lane 7-12). Moreover, it 
was revealed that PA tag was able to be not only inserted into a hairpin loop in W2 but 
also recognized by NZ-1 without optimization, because all mutants were able to be 
immunoprecipitated by NZ-1 (Fig. II-11, lane 2-6). It was suggested that PA tag was 
able to be inserted into the site near to both terminals without considering the steric 
hinderance and conformational change, because the mutant without linker sequence 
(W2_5) was able to bind to NZ-1. 
Figure II-11. PA tag can be inserted at W2 site without addition of any linker segment. PA 
tag was inserted into the site W2 with various lengths of linker (see Fig. II-2A) and the resultant 
IIb3 ectodomain mutants were subjected to the immunoprecipitation with 2H11 and NZ-1. 
Bound proteins were subjected to 7.5% SDS-PAGE under reducing condition and stained for 
protein with fluorescent dye. 
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Binding assay of NZ-1 and PA tag inserted into various loop regions 
PA tag was able to be inserted into very tight hairpin turn in W2 (Fig. II-10B) 
without linker sequence. To examine that the above result is versatile, I inserted PA tag 
into other various loop regions. I selected the nine regions, (1) a hairpin turns similar to 
W2 (W1, Cap, W3, W6, Calf-1 X-Z), (2) a long loop regions over 8-residue (Thigh F-G, 
Calf-1 E-F, Calf-2 F-G) and a long disordered loop including furin cleavage site (Calf-2 
X-Y) (Fig. II-2B, Fig. II-10). The expression of many mutants excepting W3 and W6 
were confirmed by the examination of the expression and secretion of each mutant 
heterodimer as described in W2 (Fig. II-12). It was suggested that the tag insertion was 
not structurally permitted in W3 and W6, because these integrin heterodimer were not 
detected. Since these two mutation sites exist near the calcium binding sites important 
for the stabilization of  subunit structure, these mutations may affect the calcium 
coordination (Jennings and Phillips 1982). In W1 and Calf-2 F-G, there was the 
possibility that the tag insertion affected the structural stability because they had low 
expression level. In other five mutants, it was suggested that the tag insertion did not 
affect the structure stability because these expression level was similar to wildtype. To 
examine that these mutations did not affect the integrin functions, full-length integrin 
mutants were expressed on the cell surface. As a result of examination using anti-human 
IIb monoclonal antibody 10E5, all seven mutants including W1 and Thigh F-G 
(excepting Cap that is not recognized by 10E5) had high expression level on the cell 
surface 
Figure II-12. Effect of the PA tag insertion into the IIb loop regions on the expression level. 
Various IIb mutants were co-transfected with wildtype 3 and subjected to the 
immunoprecipitation with anti-velcro antibody 2H11. Bound integrins were subjected to 7.5% 
SDS-PAGE under reducing and non-reducing condition and stained with fluorescent dye. Note 
that the mobility of the Calf-1 X-Z and Calf-2 X-Y mutant IIb chains are different from the 
wildtype, due to the elimination of an N-linked glycosylation site at N680 (for Calf-1 X-Z) and 
a furin-cleavage site at KRDRR859 (for Calf-2 X-Y).
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surface (Fig. II-13A). Moreover, these IIb3 mutants were recognized by ligand 
mimetic antibody PAC-1 that was able to bind to only the active IIb3 (Fig. II-13B). 
PAC-1 is a mimetic of fibrinogen that is original ligand of IIb3 (Taub et al. 1989; 
Ginsberg et al. 1990). Therefore, all mutated integrin had normal function, and it was 
suggested that the PA tag insertion did not affect not only the structure of IIb3 but also 
the function. 
Figure II-13. Assessment of cell surface expression and ligand binding activity of PA 
tag-inserted IIb3 mutants. (A) PDIS-2 cells (human podoplanin knockout in HEK293T cells) 
(gray area) or PDIS-2 cells transiently transfected with PA tag-inserted IIb3 (green solid line) 
were incubated with 1 g/ml 10E5 and stained with Alexa488-labeled secondary antibody 
specific for mouse IgG. (B) Ligand binding activity of PA tag-inserted IIb3. PDIS-2 cells 
transiently transfected with PA tag-inserted IIb3 were left untreated (red solid line) or 
incubated with DTT (blue solid line) and stained with Dylight680-AP3 and FITC-PAC-1. The 
histograms show the FITC fluorescence (i.e., PAC-1 binding) from the cell populations that are 
positive for AP3 staining.
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In the mutants with normal expression and function, it was examined that the 
inserted PA tag was able to be recognized by NZ-1. The mutant IIb3 ectodomain 
fragments were subjected to the immunoprecipitation with NZ-1, and immunoblotted 
with anti-velcro antibody. As a result, all mutants were able to be immunopreciated by 
NZ-1, and only wildtype without PA tag did not react (Fig. II-14, upper panel). When 
this result was compared with the immunoprecipitation results using anti-3 antibody 
7E3 (Fig. II-14, lower panel) to evaluate the total expression level of heterodimer, NZ-1 
was able to immunoprecipitate all integrin heterodimer excepting Cap mutant, and did 
not lose the recognition ability toward the inserted PA tag. In Cap mutant, PA tag was 
inserted into very short length type I -hairpin turn of 2-residue (Fig. II-10B), and it 
was suggested that PA tag could not form the suitable conformation for the recognition 
of NZ-1, because both terminals of PA tag were made to near. However, surprisingly, 
NZ-1 was able to bind to PA tag inserted into a very tight turn with some binding 
affinity. Therefore, it was expected that PA tag was able to be inserted into the middle of 
loop region of various proteins without considering the choice of insertion site and the 
addition of linker sequence, and the inserted PA tag was able to be recognized by NZ-1 
in native conformation (i.e., it was able to use as affinity tag). 
Figure II-14. Recognition of the inserted PA tag by NZ-1. The mutant IIb3 ectodomain 
fragments were expressed as in Fig. II-12 and subjected to the immunoprecipitation with NZ-1 
(upper panel) or anti-3 antibody 7E3 (lower panel). Bound proteins are separated on 7.5% 
SDS-PAGE gel under nonreducing condition, transferred to PVDF membranes, and 
immunoblotted with anti-velcro polyclonal antibody.
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Meanwhile, are these characteristics of PA tag system the unique one? 
Previously, there were no examples that the possibility of the tag insertion into loop was 
systematically examined in the popular epitope tag. Thus, I performed the examination 
using FLAG tag and Myc tag as described for PA tag. FLAG tag and Myc tag were 
inserted into three sites of integrin IIb3 (W2, Thigh F-G, Calf-1 X-Z) where the 
inserted PA tag had high affinity toward NZ-1 (Fig. II-2C). It was revealed that all 
mutations did not involve the expression and secretion of integrin heterodimer by 
immunoprecipitation with anti-3 antibody 7E3 as shown in PA tag (Fig. II-15, lane 5, 
6). It was confirmed that these tag insertion did not affect the integrin conformation. I 
was able to acknowledge this result because FLAG tag (8-residue) and Myc tag 
(10-residue) were shorter than PA tag. However, it was revealed that these all mutants 
completely lost the recognition ability toward each antibody, when I attempted to 
immunoprecipitate these mutants using each anti-tag antibody (FLAG tag; M2, Myc 
tag; 9E10) (Fig. II-15, lane 2, 3). It was suggested that the conformations of FLAG tag 
and Myc tag inserted into loop region were fixed, and the FLAG tag and the Myc tag 
were not able to be recognized by each monoclonal antibody. The structure of the 
M2/FLAG peptide complex has not been determined, on the other hand, the structure of 
the 9E10/Myc peptide complex has been determined already (Krauss et al. 2008). The 
result indicated that Myc peptide with the extended -structure is recognized by 9E10, 
and suggested that Myc tag inserted into loop region lost the affinity toward 9E10. As a 
result, it was concluded that the characteristics of PA tag that the tag inserted into loop 
region was able to function as tag with high affinity is extremely unique. 
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Figure II-15. Comparison among various epitope tags in the loop insertion application.
IIb3 ectodomain fragments with PA (lanes 1 and 4), FLAG (lanes 2 and 5), and Myc (lanes 3 
and 6) tags inserted at three different sites (W2, Thigh F-G, and Calf-1 X-Z) were 
immunoprecipitated with 7E3 (lanes 4-6) or corresponding anti-tag antivodies (lanes 1-3), and 
visualized by anti-velcro immunoblotting as in the legend to Fig. II-14. Culture supernatants 
from the mock (lane 7) and wildtype IIb3 integrin-expressing (lane 8) cells were used as 
negative and positive controls, respectively.
Usability of PA tag as research tool for integrin conformational change 
The features of PA tag that the can be inserted into a middle of a protein have 
various possibilities for research. For example, it is expected that PA tag system is able 
to detect the exposure level and accessibility of a particular region in a target protein. It 
was reported that integrin used as a model protein was dynamically changed the 
conformation (Rosano and Rocco 2010; Luo et al. 2007; Springer and Dustin 2012; 
Takagi et al. 2002b). Integrin has the bent conformation in inactive state, and has the 
extend conformation when it is activated by the ligand binding. Therefore, there are the 
epitope regions that the exposure level is different before or after the conformational 
change, and the monoclonal antibodies that recognize the regions were used as the 
reporting tool for integrin active state. These were called LIBS (ligand-induced binding 
sites) antibody (Fig. II-16) (Kouns et al. 1990; Bazzoni et al. 1995). Usually, LIBS 
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antibody was accidentally obtained from a number of antibodies. However, it is possible 
that versatile tool for the detection and induction of integrin conformational change is 
able to be constructed by using PA tag and NZ-1. 
Figure II-16. Scheme of integrin activation with LIBS antibody. (A) Conformational 
equilibrium of cell surface integrin. Four putative conformers (bent, half-bent, extend-close, and 
extend-open) are postulated to be present on cell surface, with each abundance among the 
population determined by the particular cell condition (Luo et al. 2007). The wedge below the 
cartoon represents the relative ligand-binding activity. (B) Mechanism of integrin activation by 
LIBS antibodies. In the resting state (above), most cell-surface integrins are in the bent 
conformation (i.e., low activity) but spontaneously extend and are bound by LIBS antibody. As 
the LIBS antibody-bound integrins do not bend back, the population of the extended integrins 
(highly active as denoted by eyelash) increases, leading to the overall upregulation of integrin 
activity on the cell. 
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Interestingly, as shown in Fig. II-17, the reactivity of full-length Calf-1 E-F on 
cell surface toward NZ-1 was lower than other mutants. This result corresponded to the 
fact that this inserted site was hidden inside the bent conformation in original 
conformation of integrin IIb3 on cell surface (Fig. II-18A). It was confirmed that the 
binding ability was enhanced (Fig. II-18B, left panel), when this mutant was examined 
the reactivity toward NZ-1 in the condition that integrin was activated and induced the 
ligand binding (i.e., the condition of integrin extend conformation). This change was not 
shown in other mutation sites (W2, Thigh F-G) (Fig. II-18B, middle and right panel), 
and this was the unique phenomenon for Calf-1 E-F site with increasing the exposure 
level by conformational change (extension). As a result, it was revealed that NZ-1 was 
able to be used as LIBS antibody for the conformational change reporter by the choice 
of PA tag insertion sites. 
Figure II-17. Comparison of NZ-1 staining efficiency among various PA tag-inserted IIb3
mutants. Cells expressing various mutant IIb3 were simultaneously stained with 0.5 g/ml 
NZ-1 and 1 g/ml 10E5, followed by incubation with PE-labeled anti-rat IgG and 
Alexa488-labeled anti-mouse IgG. The histogram show PE fluorescence (i.e., NZ-1 staining) for 
the 10E5-positive cell population (corresponding to the region indicated by brackets in Fig. 
II-13A). MFI (mean fluorescence intensity) value for the PE fluorescence is shown above each 
histogram. 
66
Figure II-18. The LIBS nature of the PA tag inserted at Calf-1 E-F site. (A) Location of 
the loop-insertion. The entire IIb3 ectodomain in the bent form is shown as surface 
presentation with IIb and 3 chains colored in red and gray, respectively. Locations of the loop 
insertion used in Fig. II-14 are highlighted in cyan, except for the Calf-1 E-F shown in gold. 
Note that Calf-1 E-F site is located inside the bend, partially occluded by the -propeller domain. 
(B) Conformation dependent epitope exposure. PDIS-2 cells transiently expressing IIb3 with 
three different PA-tag insertions were incubated with (1) Dylight680-AP3 alone (red solid line), 
(2) Dylight680-AP3 and FITC-NZ-1 (blue solid line), or (3) Dylight680-AP3, FITC-NZ-1, 0.5 
mM MnCl2, and 1 mM RGD peptide (green solid line). Shown are FITC fluorescence histogram 
obtained with AP3-positive cell populations. 
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As many proteins with conformational change, integrin has a state of 
equilibrium between four putative conformers (bent, half-bent, extend-close, 
extend-open) (Fig. II-16A). Therefore, it was known that LIBS antibody induces the 
integrin activation on cell surface, because the integrin of extend conformation is 
stabilized when LIBS antibody binds to integrin, and the equilibrium as described above 
is shifted to the extend conformation (Fig. II-16B) (Bazzoni et al. 1995; Dormond et al. 
2004; Luo et al. 2003). Therefore, I examined the ligand binding ability in all PA tag 
inserted mutants with or without NZ-1. As a result, the ability for integrin ligand 
binding were not changed by NZ-1 in many mutants, and only Calf-1 E-F was grown 
the PAC-1 binding ability by NZ-1 (Fig. II-19). These results suggested that NZ-1 has 
the characteristics of integrin LIBS antibody in Calf-1 E-F, and the rarely obtained 
integrin LIBS antibody (conformational change reporter and artificial activation tool) 
was able to be developed in every integrin. 
Figure II-19. Ligand binding activity of IIb3 with cryptic epitope can be activated by 
NZ-1. PDIS-2 cells transiently transfected with PA tag-inserted IIb3 were stained with 
Dylight680-AP3 and FITC-PAC-1 in the absence (red solid line), or presence (blue solid line) of 
10 g/ml NZ-1. FITC fluorescence histograms from the cell populations that are positive for 
AP3 staining are shown.
68
Discussion 
As a result of the structural analysis of the NZ-1/PA peptide complex, it was 
revealed that the complex has many contacts between the peptide and the Fab (Fig. 
II-8B). However, it is difficult to explain the reason why the binding affinity between 
PA tag and NZ-1 is high (10-9~10-12 M), because the binding surface area is as large as 
the general interface area between protein and peptide. Therefore, I discuss the reason 
why PA tag has high affinity toward NZ-1. When the apo structure was compared with 
the complex structure, these structures are essentially identical at the level of the side 
chains in the CDR, and only Lys76 and Arg120 have obvious difference in the side 
chain conformation (Fig. II-6). There are many hydrogen bonds between NZ-1 and PA 
peptide via water molecules (Fig. II-20A), and these hydrogen bonds remain in the apo 
structure by the additional water molecules in place of PA peptide (Fig. II-20B). The 
result suggested the reason why PA tag system has high affinity. The reason is that PA 
peptide can bind to NZ-1 without loss of energy, because structure of NZ-1 including 
water molecules has no major difference with or without bound PA peptide. Additionally, 
another important point is that within the binding pocket of NZ-1, the PA peptide 
assumes a tight 2-residue type II -turn conformation, with Pro7 and Gly8 being the tip 
of the hairpin (Fig. II-8A, B). It is known that Pro-Gly sequence easily structures a 
-turn (Guruprasad and Rajkumar 2000; Hutchinson and Thornton 1994). Therefore, 
this region 
Figure II-20. Surface water molecules observed at the peptide binding site of NZ-1.
Close-up view of the binding pocket of NZ-1 Fab in the peptide-bound (A) and peptide-free (B) 
states, with the interface residues shown in stick models and colored as in Fig. II-8. In (A), 
interfacial water molecules involved in hydrogen bonding network (black dotted lines) are 
shown as blue, orange, and magenta spheres, along with selected PA14 residues. In (B), three 
surface-bound waters occupying nearly identical positions are colored similarly. In addition, 
three other water molecules are present and shown as red spheres. 
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this region in PA tag is easy to form a -turn in solution without bound NZ-1. Generally, 
the linear epitope peptide does not have a fixed conformation in solution, and such 
conformation is formed when it binds to an antibody. This means that the loss of 
entropic force upon the NZ-1/PA tag interaction is relatively small, which may be the 
reason for the high affinity. In fact, it was reported that P5A and G6A mutants for the 
destruction of -turn had the severe effect in Chapter II (Fig. I-8). 
Next, it was suggested that PA tag was able to be inserted into loop regions of 
a protein, on the basis of the discovery that PA tag with turn was recognized by NZ-1. 
There were the several reports that the existing tags inserted into loop region were 
recognized by anti-tag antibody (Dinculescu et al. 2002; Smith et al. 2004; Morlacchi et 
al. 2012; Facey and Kuhn 2003; Kendall and Senogles 2006). However, these reports 
were described that linker sequence was inserted between loop and tag, and the tag 
sequence was inserted into very long loop region. As shown in Fig. II-14, NZ-1 had 
high affinity toward PA tag inserted into 5-residue loop. Furthermore, PA tag was able to 
be easily inserted into loop without linker sequence (Fig. II-11). It was suggested that 
PA tag was able to be inserted into turn/loop region without try and error for 
optimization, and this system was able to be applied various proteins, by the exhaustive 
examination using integrin IIb. Additionally, I propose that the difficult application for 
the existing tags was able to be permitted by this system of tag insertion. First, this 
system gives the third choice for protein purification, when a target protein can not be 
attached with peptide tag to N- or C-terminal because those regions are important for 
the protein function and conformation. For example, this system can prepare an 
antibody that is accessible from extracellular area to multi-pass membrane protein with 
both terminals buried intracellular area (Deng et al. 2014). Second, this system enables 
the site-specific fluorescent labeling of a protein using the high affinity (extremely slow 
dissociation rate) between PA tag and NZ-1, because PA tag can be inserted into various 
sites of protein without affecting on the protein conformation and function. Particularly, 
it is possible that FRET (fluorescence resonance energy transfer) probe for monitoring 
the conformational change and molecular assembly of protein can be introduced with 
high accuracy, and the specific labeling of domain and subunit can be accomplished in 
electron microscope. Third, NZ-1 can be used as a protein conformational change 
reporter and inducer by the choice of PA tag insertion sites (Fig. II-18, 19). Integrin 
IIb3 has many LIBS antibodies (Luo et al. 2003), and use of these antibodies facilitates 
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the research. However, LIBS antibodies were not obtained in all integrin, and especially 
the reporter antibody for integrin excepting human species was rarely given. 
Additionally, it was difficult for comparison between the examination results using 
different reporter/activate antibodies, because the affinity and isotype was different with 
each antibody. In contrast, it is possible that PA tag system can examine the 
conformational change of integrin without LIBS antibodies, and compare the kinetics of 
various LIBS epitope exposure level in an integrin. This application may be used for the 
conformational change research of various receptors. Finally, this system may be used 
as a crystallization accelerator. Recently, the co-crystallization with antibody fragment 
for the fixing structure and the providing various packing surface is general method in 
the crystallization of membrane and low crystallizability proteins (Hino et al. 2012; 
Manolaridis et al. 2013). However, the exiting tag system is not suitable for this purpose, 
because usually the antibody that recognizes the tag artificially fused to flexible region 
moves considerably with tag sequence. When PA tag is inserted into hairpin loop, it is 
possible that NZ-1 is usable crystallization accelerator (crystallization chaperon), as an 
antibody recognizing the three dimensional structure of a target protein. 
In conclusion, NZ-1 recognizes PA tag with unique conformation. Moreover, 
it was indicated that PA tag inserted into loop could be recognized by NZ-1, because PA 
tag has the unique structure. These facts suggested that PA tag system can be used not 
only as protein detection and purification system, but also as various tools for analysis 
of protein function that is impossible in the existing tag systems. 
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